<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2679680-A1" country="EP" doc-number="2679680" kind="A1" date="20140101" family-id="46720591" file-reference-id="250187" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146550390" ucid="EP-2679680-A1"><document-id><country>EP</country><doc-number>2679680</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12749381-A" is-representative="YES"><document-id mxw-id="PAPP154824313" load-source="docdb" format="epo"><country>EP</country><doc-number>12749381</doc-number><kind>A</kind><date>20120119</date><lang>JA</lang></document-id><document-id mxw-id="PAPP191080945" load-source="docdb" format="original"><country>EP</country><doc-number>12749381.5</doc-number><date>20120119</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140451753" ucid="JP-2011035289-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2011035289</doc-number><kind>A</kind><date>20110222</date></document-id></priority-claim><priority-claim mxw-id="PPC140448825" ucid="JP-2012051084-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2012051084</doc-number><kind>W</kind><date>20120119</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2066399270" load-source="docdb">C12N  15/09        20060101AFI20140328BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2066399271" load-source="docdb">C12N   1/21        20060101ALI20140328BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2066399272" load-source="docdb">C12N   9/88        20060101ALI20140328BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2066399273" load-source="docdb">C12P  13/12        20060101ALI20140328BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988111229" load-source="docdb" scheme="CPC">C12P  13/12        20130101 FI20131019BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988121819" load-source="docdb" scheme="CPC">C12N   9/88        20130101 LI20131019BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988122712" load-source="docdb" scheme="CPC">C12Y 401/01011     20130101 LI20131010BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132183654" lang="DE" load-source="patent-office">L-CYSTEIN-PRODUZIERENDES BAKTERIUM UND VERFAHREN ZUR HERSTELLUNG VON L-CYSTEIN</invention-title><invention-title mxw-id="PT132183655" lang="EN" load-source="patent-office">L-CYSTEINE-PRODUCING BACTERIUM AND METHOD FOR PRODUCING L-CYSTEINE</invention-title><invention-title mxw-id="PT132183656" lang="FR" load-source="patent-office">BACTÉRIE PRODUISANT DE LA L-CYSTÉINE ET PROCÉDÉ DE PRODUCTION DE L-CYSTÉINE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918134490" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>AJINOMOTO KK</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR918168495" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>AJINOMOTO CO., INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR918989823" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Ajinomoto Co., Inc.</last-name><iid>101020647</iid><address><street>15-1, Kyobashi 1-chome Chuo-ku</street><city>Tokyo 104-8315</city><country>JP</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918133827" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>TAKUMI KAZUHIRO</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR918166351" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>TAKUMI, KAZUHIRO</last-name></addressbook></inventor><inventor mxw-id="PPAR918989188" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>TAKUMI, KAZUHIRO</last-name><address><street>c/o AJINOMOTO CO. INC. 1-1 Suzuki-cho Kawasaki-ku</street><city>Kawasaki-shi Kanagawa 210-8681</city><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR918133897" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>NONAKA GEN</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR918132045" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>NONAKA, GEN</last-name></addressbook></inventor><inventor mxw-id="PPAR918988047" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>NONAKA, GEN</last-name><address><street>c/o AJINOMOTO CO. INC. 1-1 Suzuki-cho Kawasaki-ku</street><city>Kawasaki-shi Kanagawa 210-8681</city><country>JP</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918984863" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Strehl Schübel-Hopf &amp; Partner</last-name><iid>100060622</iid><address><street>Maximilianstrasse 54</street><city>80538 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="JP-2012051084-W"><document-id><country>JP</country><doc-number>2012051084</doc-number><kind>W</kind><date>20120119</date><lang>JA</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012114802-A1"><document-id><country>WO</country><doc-number>2012114802</doc-number><kind>A1</kind><date>20120830</date><lang>JA</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548908063" load-source="docdb">AL</country><country mxw-id="DS548905221" load-source="docdb">AT</country><country mxw-id="DS548908064" load-source="docdb">BE</country><country mxw-id="DS548909187" load-source="docdb">BG</country><country mxw-id="DS548893467" load-source="docdb">CH</country><country mxw-id="DS548827086" load-source="docdb">CY</country><country mxw-id="DS548905262" load-source="docdb">CZ</country><country mxw-id="DS548857336" load-source="docdb">DE</country><country mxw-id="DS548827087" load-source="docdb">DK</country><country mxw-id="DS548827088" load-source="docdb">EE</country><country mxw-id="DS548811166" load-source="docdb">ES</country><country mxw-id="DS548909188" load-source="docdb">FI</country><country mxw-id="DS548909189" load-source="docdb">FR</country><country mxw-id="DS548908065" load-source="docdb">GB</country><country mxw-id="DS548908074" load-source="docdb">GR</country><country mxw-id="DS548908075" load-source="docdb">HR</country><country mxw-id="DS548905263" load-source="docdb">HU</country><country mxw-id="DS548893468" load-source="docdb">IE</country><country mxw-id="DS548908076" load-source="docdb">IS</country><country mxw-id="DS548909266" load-source="docdb">IT</country><country mxw-id="DS548827089" load-source="docdb">LI</country><country mxw-id="DS548857337" load-source="docdb">LT</country><country mxw-id="DS548905264" load-source="docdb">LU</country><country mxw-id="DS548857338" load-source="docdb">LV</country><country mxw-id="DS548857339" load-source="docdb">MC</country><country mxw-id="DS548914427" load-source="docdb">MK</country><country mxw-id="DS548914428" load-source="docdb">MT</country><country mxw-id="DS548811167" load-source="docdb">NL</country><country mxw-id="DS548905265" load-source="docdb">NO</country><country mxw-id="DS548811168" load-source="docdb">PL</country><country mxw-id="DS548827090" load-source="docdb">PT</country><country mxw-id="DS548811169" load-source="docdb">RO</country><country mxw-id="DS548827091" load-source="docdb">RS</country><country mxw-id="DS548811170" load-source="docdb">SE</country><country mxw-id="DS548827092" load-source="docdb">SI</country><country mxw-id="DS548914429" load-source="docdb">SK</country><country mxw-id="DS548914502" load-source="docdb">SM</country><country mxw-id="DS548893469" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671057" lang="EN" load-source="patent-office"><p id="pa01" num="0001">A novel technique for improving L-cysteine-producing ability of bacteria is developed, and thereby an L-cysteine-producing bacterium and a method for producing compounds such as L-cysteine are provided. L-cysteine, a related substance thereof, or a mixture thereof is produced by culturing a bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability, and is modified so that L-aspartate-α-decarboxylase activity is increased, in a medium, and collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</p></abstract><abstract mxw-id="PA128500430" lang="EN" source="EPO" load-source="docdb"><p>A novel technique for improving L-cysteine-producing ability of bacteria is developed, and thereby an L-cysteine-producing bacterium and a method for producing compounds such as L-cysteine are provided. L-cysteine, a related substance thereof, or a mixture thereof is produced by culturing a bacterium belonging to the family  Enterobacteriaceae,  which has L-cysteine-producing ability, and is modified so that L-aspartate-±-decarboxylase activity is increased, in a medium, and collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</p></abstract><description mxw-id="PDES63956487" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">Field of the Invention</heading><p id="p0001" num="0001">The present invention relates to a method for producing L-cysteine or a related substance thereof. Specifically, the present invention relates to a bacterium suitable for the production of L-cysteine or a related substance thereof and a method for producing L-cysteine or a related substance thereof utilizing such a bacterium. L-cysteine and related substances thereof are used in the fields of drugs, cosmetics, and foods.</p><heading id="h0002">Background Art</heading><p id="p0002" num="0002">L-cysteine is conventionally obtained by extraction from keratin-containing substances such as hairs, horns, and feathers or conversion of DL-2-aminothiazoline-4-carboxylic acid as a precursor using a microbial enzyme. It is also planned to produce L-cysteine in a large scale by an immobilized enzyme method utilizing a novel enzyme. Furthermore, it is also attempted to produce L-cysteine by fermentation utilizing a microorganism.</p><p id="p0003" num="0003">As microorganisms having an ability to produce L-cysteine, there is known, for example, a coryneform bacterium of which intracellular serine acetyltransferase activity is increased (Patent document 1). There is also known a technique of enhancing L-cysteine-producing ability by incorporating a mutant serine acetyltransferase of which<!-- EPO <DP n="2"> --> feedback inhibition by L-cysteine is attenuated (Patent documents 2 to 4).</p><p id="p0004" num="0004">Furthermore, as microorganisms of which L-cysteine-producing ability is enhanced by suppressing the L-cysteine decomposition system, there are known coryneform bacteria or <i>Escherichia</i> bacteria in which activity of cystathionine-β-lease (Patent document 2), tryptophanase (Patent document 5), or O-acetylserine sulfhydrylase B (Patent document 6) is decreased or deleted.</p><p id="p0005" num="0005">Furthermore, it is known that the ydeD gene which encodes the YdeD protein participates in secretion of the metabolic products of the cysteine pathway (Non-patent document 1). Furthermore, there are also known techniques of enhancing L-cysteine-producing ability by increasing expression of the <i>mar</i>-locus, <i>emr</i>-locus, <i>acr</i>-locus, <i>cmr-</i>locus, <i>mex</i>-gene, <i>bmr</i>-gene, or <i>qacA</i>-gene, which encodes a protein suitable for secreting a toxic substance from cells (Patent document 7), or <i>emrAB, emrKY, yojIH, acrEF, bcr,</i> or <i>cusA</i> gene (Patent document 8).</p><p id="p0006" num="0006">Furthermore, as an L-cysteine-producing bacterium, there is known <i>Escherichia coli</i> of which activity of the positive transcriptional regulator of the cysteine regulon encoded by the <i>cysB</i> gene is increased (Patent document 9).</p><p id="p0007" num="0007">Furthermore, there is known a mutant serA gene coding for 3-phosphoglycerate dehydrogenase of which feedback inhibition by serine is attenuated, and use thereof for L-cysteine production by <i>Escherichia coli</i> has been suggested (Patent documents 10 and 11).</p><p id="p0008" num="0008"><!-- EPO <DP n="3"> --> L-aspartate-α-decarboxylase (EC 4.1.1.11) is an enzyme that catalyzes the reaction of decarboxylating L-aspartic acid thereby to generate β-alanine. It is known that L-aspartate-α-decarboxylase is generally translated as an inactive precursor protein, then subjected to processing at a specific site, and thus becomes an active protein. Although it is known that L-aspartate-α-decarboxylase suffers from competitive inhibition in the presence of L-cysteic acid (Non-patent document 2), it is not known whether it is inhibited by L-cysteine.</p><p id="p0009" num="0009">β-Alanine generated by the catalytic reaction of L-aspartate-α-decarboxylase is used as an intermediate for the biosynthesis of pantothenic acid. Pantothenic acid is converted into coenzyme A (CoA), and then used within organisms. Therefore, L-aspartate-α-decarboxylase can be a key enzyme of the biosynthesis of acetyl-CoA (Non-patent document 3). However, it is not known whether the biosynthesis of acetyl-CoA can be a rate-limiting factor of the production of L-cysteine.</p><p id="p0010" num="0010">It is known that enhancing expression of the <i>panD</i> gene encoding L-aspartate-α-decarboxylase increases the production amount of pantothenic acid (Non-patent document 4). Moreover, there is known a method for producing L-glutamic acid by using a medium containing pantothenic acid (Patent document 12).</p><p id="p0011" num="0011">However, any relationship between L-aspartate-α-decarboxylase or pantothenic acid and L-cysteine production is not known.</p><heading id="h0003">Prior art references</heading><!-- EPO <DP n="4"> --><heading id="h0004">Patent documents</heading><p id="p0012" num="0012"><ul><li>Patent document 1: Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0001" dnum="JP2002233384A"><text>2002-233384</text></patcit></li><li>Patent document 2: Japanese Patent Laid-open No. <patcit id="pcit0002" dnum="JP11155571A"><text>11-155571</text></patcit></li><li>Patent document 3: <patcit id="pcit0003" dnum="US20050112731A"><text>U.S. Patent Published Application No. 2005-0112731</text></patcit></li><li>Patent document 4: <patcit id="pcit0004" dnum="US6218168B"><text>U.S. Patent No. 6,218,168</text></patcit></li><li>Patent document 5: Japanese Patent Laid-open No. <patcit id="pcit0005" dnum="JP2003169668A"><text>2003-169668</text></patcit></li><li>Patent document 6: Japanese Patent Laid-open No. <patcit id="pcit0006" dnum="JP2005245311A"><text>2005-245311</text></patcit></li><li>Patent document 7: <patcit id="pcit0007" dnum="US5972663A"><text>U.S. Patent No. 5,972,663</text></patcit></li><li>Patent document 8: Japanese Patent Laid-open No. <patcit id="pcit0008" dnum="JP2005287333A"><text>2005-287333</text></patcit></li><li>Patent document 9: International Patent Publication <patcit id="pcit0009" dnum="WO0127307A"><text>WO01/27307</text></patcit></li><li>Patent document 10: <patcit id="pcit0010" dnum="US5856148A"><text>U.S. Patent No. 5,856,148</text></patcit></li><li>Patent document 11: <patcit id="pcit0011" dnum="US20050009162A"><text>U.S. Patent Published Application No. 2005-0009162</text></patcit></li><li>Patent document 12: International Patent Publication <patcit id="pcit0012" dnum="WO2004111258A"><text>WO2004/111258</text></patcit></li></ul></p><heading id="h0005">Non-patent documents</heading><p id="p0013" num="0013"><ul><li>Non-patent document 1: <nplcit id="ncit0001" npl-type="s"><text>Dassler et al., Mol. Microbiol., 36, 1101-1112 (2000</text></nplcit>)</li><li>Non-patent document 2: <nplcit id="ncit0002" npl-type="s"><text>Williamson JM. et al., J. Biol. Chem., 1979, Aug 25;254 (16):8074-82</text></nplcit></li><li>Non-patent document 3: <nplcit id="ncit0003" npl-type="s"><text>Kennedy J. et al., Anal. Biochem., 2004, Apr 1;327(1):91-6</text></nplcit></li><li>Non-patent document 4: <nplcit id="ncit0004" npl-type="s"><text>Dusch N. et al., Appl. Environ. Microbiol., 1999 Apr;65(4):1530-9</text></nplcit></li></ul><!-- EPO <DP n="5"> --></p><heading id="h0006">Disclosure of the Invention</heading><heading id="h0007">Object to be Achieved by the Invention</heading><p id="p0014" num="0014">An object of the present invention is to develop a novel technique for improving L-cysteine-producing ability of bacteria and thereby provide an L-cysteine-producing bacterium and a method for producing L-cysteine, a related substance thereof, or a mixture thereof using the bacterium.</p><heading id="h0008">Means for Achieving the Object</heading><p id="p0015" num="0015">The inventor of the present invention conducted various researches in order to achieve the aforementioned object, and as a result, found that by modifying a bacterium so that L-aspartate-α-decarboxylase activity thereof was increased, L-cysteine-producing ability of the bacterium could be improved. The inventor of the present invention further found that by adding pantothenic acid to a medium used for L-cysteine production, L-cysteine-producing ability could be improved. The present invention was accomplished on the basis of the above findings.</p><p id="p0016" num="0016">The present invention can be thus embodied as follows.
<ol><li>[1] A bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability, and is modified so that L-aspartate-α-decarboxylase activity is increased.</li><li>[2] The bacterium as mentioned above, wherein the L-aspartate-α-decarboxylase activity is increased by increasing the expression amount of <i>panD</i> gene.</li><li>[3]<!-- EPO <DP n="6"> --> The bacterium as mentioned above, wherein the expression amount of the <i>panD</i> gene is increased by increasing the copy number of the <i>panD</i> gene or by modifying an expression control sequence of the <i>panD</i> gene.</li><li>[4] The bacterium as mentioned above, wherein the <i>panD</i> gene is a DNA coding for a protein of the following (A) or (B):
<ol><li>(A) a protein comprising the amino acid sequence of SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60;</li><li>(B) a protein comprising the amino acid sequence of SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60 but which includes one or several amino acid substitutions, deletions, insertions, or additions, and having the L-aspartate-α-decarboxylase activity.</li></ol></li><li>[5] The bacterium as mentioned above, wherein the <i>panD</i> gene is a DNA of the following (a) or (b):
<ol><li>(a) a DNA comprising the nucleotide sequence of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, or 59;</li><li>(b) a DNA hybridizable with a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, or 59, or a probe that can be prepared from the nucleotide sequence under stringent conditions, and coding for a protein having the L-aspartate-α-decarboxylase activity.</li></ol></li><li>[6] The bacterium as mentioned above, wherein the protein having the L-aspartate-α-decarboxylase activity has the<!-- EPO <DP n="7"> --> following characteristics (1) and (2):
<ol><li>(1) the glycine residue of position 24 and the serine residue of position 25 are conserved;</li><li>(2) the lysine residue of position 9, the histidine residue of position 11, the threonine residue of position 57, and the tyrosine residue of position 58 are conserved.</li></ol></li><li>[7] The bacterium as mentioned above, wherein the protein having the L-aspartate-α-decarboxylase activity further has the following characteristic (3):
<ul><li>(3) the valine residue of position 15, the threonine residue of position 16, the leucine residue of position 20, the tyrosine residue of position 22, the aspartic acid residue of position 29, the glutamic acid residue of position 42, the asparagine residue of position 51, the glycine residue of position 52, the arginine residue of position 54, the isoleucine residue of position 60, the asparagine residue of position 72, the glycine residue of position 73, the alanine residue of position 74, the alanine residue of position 75, the alanine residue of position 76, the aspartic acid residue of position 83, and the isoleucine residue of position 86 are conserved.</li></ul></li><li>[8] The bacterium as mentioned above, which further has one or more of the following characteristics (1) to (3):
<ol><li>(1) it is modified so that the serine acetyltransferase activity is increased;</li><li>(2) L-cysteine excretion system is enhanced;</li><li>(3) it is modified so that the 3-phosphoglycerate dehydrogenase activity is increased.</li></ol></li><li>[9] The bacterium as mentioned above, which is an <i>Escherichia</i> bacterium.<!-- EPO <DP n="8"> --></li><li>[10] The bacterium as mentioned above, which is <i>Escherichia coli.</i></li><li>[11] The bacterium as mentioned above, which is a <i>Pantoea</i> bacterium.</li><li>[12] The bacterium as mentioned above, which is <i>Pantoea ananatis.</i></li><li>[13] A method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
<ul><li>culturing the bacterium as mentioned above in a medium; and</li><li>collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</li></ul></li><li>[14] The method as mentioned above, wherein the medium contains pantothenic acid.</li><li>[15] A method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
<ul><li>culturing a bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability, in a medium containing pantothenic acid; and</li><li>collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</li></ul></li><li>[16] The method as mentioned above, wherein the contained amount of pantothenic acid in the medium is 1 mg/L or more.</li><li>[17] The method as mentioned above, wherein the related substance of L-cysteine is L-cystine, a thiazolidine<!-- EPO <DP n="9"> --> derivative, or L-methionine.</li></ol></p><heading id="h0009">Brief Description of the Drawings</heading><p id="p0017" num="0017"><ul><li><figref idrefs="f0001 f0002 f0003 f0004">Fig. 1</figref> shows alignment of PanD proteins derived from various bacteria. The conserved amino acid residues are boxed.</li><li><figref idrefs="f0002 f0003 f0004">Fig. 2</figref> shows L-cysteine production amounts obtained with addition of pantothenic acid at various concentrations.</li></ul></p><heading id="h0010">Modes for Carrying out the Invention</heading><heading id="h0011">&lt;1&gt; Bacterium of the present invention</heading><p id="p0018" num="0018">The bacterium of the present invention is a bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability and is modified so that the L-aspartate-α-decarboxylase activity is increased.</p><p id="p0019" num="0019">In the present invention, L-cysteine can be L-cysteine in the free form, a salt thereof, or a mixture of them. Examples of the salt include, for example, sulfate, hydrochloride, carbonate, ammonium salt, sodium salt, and potassium salt.</p><p id="p0020" num="0020">In the present invention, the L-cysteine-producing ability refers to an ability of a bacterium to produce L-cysteine, a related substance thereof, or a mixture thereof and accumulate it in a medium or cells of the bacterium in such an amount that L-cysteine, the related substance thereof, or the mixture thereof can be collected from the medium or cells, when the bacterium is cultured in the medium. A bacterium having L-cysteine-producing ability means a bacterium that can produce and accumulate L-cysteine,<!-- EPO <DP n="10"> --> a related substance thereof, or a mixture thereof in a medium or cells in a larger amount compared with a wild-type strain or a parent strain. A bacterium having L-cysteine-producing ability preferably means a bacterium that can produce and accumulate L-cysteine, a related substance thereof, or a mixture thereof in a medium in an amount of 0.05 g/L or more, more preferably 0.1 g/L or more, particularly preferably 0.2 g/L or more.</p><p id="p0021" num="0021">A portion of L-cysteine produced by the bacterium can be converted into L-cystine in the medium by formation of a disulfide bond. Further, S-sulfocysteine can be generated by the reaction of L-cysteine and thiosulfate contained in the medium (<nplcit id="ncit0005" npl-type="s"><text>Szczepkowski T.W., Nature, vol. 182 (1958</text></nplcit>)). Furthermore, L-cysteine generated in bacterial cells can be condensed with a ketone or aldehyde, for example, pyruvic acid, which exists in the cells, to produce a thiazolidine derivative via a hemithioketal as an intermediate (refer to Japanese Patent No. <patcit id="pcit0013" dnum="JP2992010B"><text>2992010</text></patcit>). These thiazolidine derivative and hemithioketal can exist as an equilibrated mixture.</p><p id="p0022" num="0022">Further, L-cysteine is used as a starting material of the biosyntheses of γ-glutamylcysteine, glutathione, cystathionine, homocysteine, L-methionine, S-adenosylmethionine, and so forth. Therefore, by using a bacterium having an ability to produce any of these compounds to be produced via L-cysteine in addition to the ability to produce L-cysteine, these compounds can be produced.</p><p id="p0023" num="0023">Therefore, in the present invention, the L-cysteine-producing ability is not limited to an ability to<!-- EPO <DP n="11"> --> accumulate only L-cysteine in a medium or cells, but also includes an ability to accumulate L-cysteine, L-cystine, such a derivative of L-cysteine as mentioned above (for example, S-sulfocysteine, a thiazolidine derivative, and a hemithioketal), such a compound to be produced via L-cysteine as mentioned above (for example, γ-glutamylcysteine, glutathione, cystathionine, homocysteine, L-methionine, and S-adenosylmethionine), or a mixture thereof in the medium or cells. In the present invention, L-cystine, such a derivative of L-cysteine as mentioned above and such a compound to be produced via L-cysteine as mentioned above are collectively referred to as a related substance of L-cysteine.</p><p id="p0024" num="0024">The bacterium having L-cysteine-producing ability can be a bacterium inherently having L-cysteine-producing ability, or it can be obtained by modifying a microorganism such as those described below by mutagenesis or a recombinant DNA technique so that it acquires L-cysteine-producing ability.</p><p id="p0025" num="0025">The bacterium used for the present invention is not particularly limited, so long as a bacterium belonging to the family <i>Enterobacteriaceae</i> such as those of the genera <i>Escherichia, Enterobacter, Pantoea, Klebsiella, Serratia, Erwinia, Salmonella,</i> and <i>Morganella</i> and having L-cysteine-producing ability is chosen. Specifically, those classified into the family <i>Enterobacteriaceae</i> according to the taxonomy used in the NCBI (National Center for Biotechnology Information) database (http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id 91347) can be used. As a parent strain of the family <i>Enterobacteriaceae</i> used for the modification, it is<!-- EPO <DP n="12"> --> desirable to use, especially, a bacterium of the genus <i>Escherichia, Enterobacter, Pantoea, Erwinia, Enterobacter,</i> or <i>Klebsiella.</i></p><p id="p0026" num="0026">Although the <i>Escherichia</i> bacteria are not particularly limited, specifically, those described in the work of Neidhardt et al. (<nplcit id="ncit0006" npl-type="b"><text>Backmann B.J., 1996, Derivations and Genotypes of some mutant derivatives of Escherichia coli K-12, p.2460-2488, Table 1, In F.D. Neidhardt (ed.), Escherichia coli and Salmonella Cellular and Molecular Biology/Second Edition, American Society for Microbiology Press, Washington, D.C</text></nplcit>.) can be used. Examples of <i>Escherichia</i> bacteria include, for example, <i>Escherichia coli.</i> Specific examples of <i>Escherichia coli</i> include the <i>Escherichia coli</i> W3110 strain (ATCC 27325), <i>Escherichia coli</i> MG1655 strain (ATCC 47076) and so forth derived from the prototype wild-type strain, K12 strain.</p><p id="p0027" num="0027">These strains are available from, for example, the American Type Culture Collection (Address: 12301 Parklawn Drive, Rockville, Maryland 20852, P.O. Box 1549, Manassas, VA 20108, United States of America). That is, registration numbers are given to each of the strains, and the strains can be ordered by using these registration numbers (refer to http://www.atcc.org/). The registration numbers of the strains are listed in the catalogue of the American Type Culture Collection.</p><p id="p0028" num="0028">Examples of the <i>Enterobacter</i> bacteria include, for example, <i>Enterobacter agglomerans</i> and <i>Enterobacter aerogenes.</i> An example of typical strains of the genus <i>Enterobacter</i> includes <i>Enterobacter agglomerans</i> ATCC 12287 strain. Also, specifically, the strains exemplified in<!-- EPO <DP n="13"> --> European Patent Publication No. <patcit id="pcit0014" dnum="EP952221A"><text>952221</text></patcit> can be used.</p><p id="p0029" num="0029">Examples of the <i>Pantoea</i> bacteria include, for example, <i>Pantoea ananatis, Pantoea stewartii, Pantoea agglomerans,</i> and <i>Pantoea citrea.</i></p><p id="p0030" num="0030">Specific examples of <i>Pantoea ananatis</i> include the <i>Pantoea ananatis</i> AJ13355 strain (FERM BP-6614) and SC17 strain (FERM BP-11091). The AJ13355 strain is a strain isolated from soil in Iwata-shi, Shizuoka-ken, Japan as a strain that can proliferate in a low pH medium containing L-glutamic acid and a carbon source. The SC17 strain is a strain selected as a low phlegm-producing mutant strain from the AJ13355 strain (<patcit id="pcit0015" dnum="US6596517B"><text>U.S. Patent No. 6,596,517</text></patcit>). The <i>Pantoea ananatis</i> AJ13355 strain was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Address: Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on February 19, 1998 and assigned an accession number of FERM P-16644. It was then converted to an international deposit under the provisions of Budapest Treaty on January 11, 1999 and assigned an accession number of FERM BP-6614. The <i>Pantoea ananatis</i> SC17 strain was deposited at the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (Address: Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on February 4, 2009 and assigned an accession number of FERM BP-11091. The <i>Pantoea ananatis</i> AJ13355 strain was identified as <i>Enterobacter agglomerans</i> when it was isolated,<!-- EPO <DP n="14"> --> and deposited as the <i>Enterobacter agglomerans</i> AJ13355 strain. However, it was recently reclassified into <i>Pantoea ananatis</i> on the basis of nucleotide sequence analysis of 16S rRNA and so forth.</p><p id="p0031" num="0031">Examples of the <i>Erwinia</i> bacteria include <i>Erwinia amylovora</i> and <i>Erwinia carotovora,</i> and examples of the <i>Klebsiella</i> bacteria include <i>Klebsiella planticola.</i></p><p id="p0032" num="0032">In particular, <i>Pantoea</i> bacteria, <i>Erwinia</i> bacteria, and <i>Enterobacter</i> bacteria are classified as γ-proteobacteria, and they are taxonomically very close to one another (<nplcit id="ncit0007" npl-type="s"><text>J. Gen. Appl. Microbiol., 1997, 43, 355-361</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>International Journal of Systematic Bacteriology, Oct. 1997, pp.1061-1067</text></nplcit>). Therefore, some bacteria belonging to the genus <i>Enterobacter</i> were reclassified into <i>Pantoea agglomerans, Pantoea dispersa,</i> or the like, on the basis of DNA-DNA hybridization experiments etc. (<nplcit id="ncit0009" npl-type="s"><text>International Journal of Systematic Bacteriology, July 1989, 39(3), pp.337-345</text></nplcit>). For example, some strains of <i>Enterobacter agglomerans</i> were reclassified into <i>Pantoea agglomerans, Pantoea ananatis,</i> or <i>Pantoea stewartii</i> on the basis of nucleotide sequence analysis of 16S rRNA etc. Furthermore, some bacteria belonging to the genus <i>Erwinia</i> were reclassified into <i>Pantoea ananas</i> or <i>Pantoea stewartii</i> (refer to <nplcit id="ncit0010" npl-type="s"><text>International Journal of Systematic Bacteriology, Jan 1993;43(1), pp.162-173</text></nplcit>). In the present invention, a bacterium belonging to any of the genus <i>Enterobacter, Pantoea, Erwinia,</i> and the like can be used so long as it is a bacterium classified into the family <i>Enterobacteriaceae.</i></p><p id="p0033" num="0033">Methods for imparting L-cysteine-producing ability to bacteria belonging to the family <i>Enterobacteriaceae</i> and<!-- EPO <DP n="15"> --> methods for enhancing L-cysteine-producing ability of such bacteria are described below.</p><p id="p0034" num="0034">To impart L-cysteine-producing ability to a bacterium, methods conventionally employed in the breeding of coryneform bacteria, <i>Escherichia</i> bacteria, and so forth can be used. Such methods include acquiring an auxotrophic mutant strain, an analogue resistant strain, or a metabolic regulation mutant strain, or constructing a recombinant strain in which an L-cysteine biosynthesis enzyme is overexpressed, and so forth (see "<nplcit id="ncit0011" npl-type="b"><text>Amino Acid Fermentation", Gakkai Shuppan Center (Ltd.), 1st Edition, published May 30, 1986, pp.77-100</text></nplcit>). In the breeding of L-cysteine-producing bacteria, one or two or more kinds of the above-described properties such as auxotrophy, analogue resistance, and metabolic regulation mutation can be imparted. Also, expression of one or two or more kinds of the L-cysteine biosynthesis enzymes can be enhanced. Furthermore, imparting such properties as auxotrophy, analogue resistance, and metabolic regulation mutation can be combined with enhancing a biosynthesis enzyme.</p><p id="p0035" num="0035">An auxotrophic mutant strain, L-cysteine analogue resistant strain, or metabolic regulation mutant strain having L-cysteine-producing ability can be obtained by subjecting a parent strain or wild-type strain to conventional mutagenesis, such as exposure to X-rays or UV irradiation or a treatment with a mutagen such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) or ethyl methanesulfonate (EMS), and then selecting a strain exhibiting autotrophy, analogue resistance or a metabolic regulation mutation and having L-cysteine-producing ability from the obtained mutant strains.<!-- EPO <DP n="16"> --></p><p id="p0036" num="0036">Methods for imparting L-cysteine-producing ability to bacteria belonging to the family <i>Enterobacteriaceae</i> or enhancing L-cysteine-producing ability of such bacteria, and bacteria having L-cysteine-producing ability are specifically exemplified below.</p><heading id="h0012">&lt;Impartation or enhancement of L-cysteine-producing ability, and L-cysteine-producing bacteria&gt;</heading><p id="p0037" num="0037">L-cysteine-producing ability of a bacterium can be improved by enhancing the activity of an enzyme of the L-cysteine biosynthesis pathway or an enzyme involved in synthesis of a compound serving as a substrate in the L-cysteine biosynthesis pathway, such as L-serine. Examples of such enzymes include serine acetyltransferase (SAT) and 3-phosphoglycerate dehydrogenase (PGD). Enhancement of an enzymatic activity can be attained by enhancing expression of a gene coding for the objective enzyme, or by enhancing specific activity of the objective enzyme, as described later. Because serine acetyltransferase is inhibited by feedback inhibition by L-cysteine, the enzymatic activity of this enzyme can be enhanced by, in particular, incorporating a mutant type <i>cysE</i> gene coding for serine acetyltransferase of which feedback inhibition is attenuated or eliminated into a bacterium. Further, because 3-phosphoglycerate dehydrogenase is inhibited by feedback inhibition by serine, the enzymatic activity of this enzyme can be enhanced by, in particular, incorporating a mutant type <i>serA</i> gene coding for a mutant 3-phosphoglycerate dehydrogenase of which feedback inhibition is attenuated or eliminated into a bacterium.</p><p id="p0038" num="0038">As mutant SAT which is derived from <i>Escherichia coli</i><!-- EPO <DP n="17"> --> and resistant to feedback inhibition, there are specifically known the mutant SAT in which the methionine residue at position 256 is replaced with glutamate residue (Japanese Patent Laid-open No. <patcit id="pcit0016" dnum="JP11155571A"><text>11-155571</text></patcit>), the mutant SAT in which the methionine residue at position 256 is replaced with isoleucine residue (<nplcit id="ncit0012" npl-type="s"><text>Denk, D. and Boeck, A., J. General Microbiol., 133, 515-525 (1987</text></nplcit>)), the mutant SAT having a mutation in the region from the amino acid residue at position 97 to the amino acid residue at position 273 or deletion of the C-terminus region from the amino acid residue at position 227 (International Patent Publication <patcit id="pcit0017" dnum="WO9715673A"><text>WO97/15673</text></patcit>, <patcit id="pcit0018" dnum="US6218168B"><text>U.S. Patent No. 6,218,168</text></patcit>), the mutant SAT in which the amino acid sequence corresponding to positions 89 to 96 of wild-type SAT contains one or more mutations, and which is desensitized to feedback inhibition by L-cysteine (<patcit id="pcit0019" dnum="US20050112731A1"><text>U.S. Patent Published Application No. 20050112731(A1</text></patcit>)), the mutant SAT in which the Val residue and the Asp residue at positions 95 and 96 of wild-type SAT are replaced with Arg residue and Pro residue, respectively (name of the mutant gene: <i>cysE5,</i> <patcit id="pcit0020" dnum="US20050112731A1"><text>U.S. Patent Published Application No. 20050112731(A1</text></patcit>)), the mutant SAT in which the threonine residue at position 167 is replaced with an alanine residue (<patcit id="pcit0021" dnum="US6218168B"><text>U.S. Patent No. 6,218,168</text></patcit>, <patcit id="pcit0022" dnum="US20050112731A1"><text>U.S. Patent Published Application No. 20050112731(A1</text></patcit>)), and so forth.</p><p id="p0039" num="0039">The gene coding for SAT is not limited to the gene of <i>Escherichia coli,</i> and any gene coding for a protein having the SAT activity can be used. For example, an SAT isozyme of <i>Arabidopsis thaliana</i> desensitized to feedback inhibition by L-cysteine is known, and the gene encoding this SAT can also be used (<nplcit id="ncit0013" npl-type="s"><text>FEMS Microbiol. Lett., 179, 453-459 (1999</text></nplcit>)).</p><p id="p0040" num="0040">Further, as a gene coding for a mutant PGD resistant<!-- EPO <DP n="18"> --> to feedback inhibition by serine, the <i>serA5</i> gene (<patcit id="pcit0023" dnum="US6180373B"><text>U.S. Patent No. 6,180,373</text></patcit>) is known.</p><p id="p0041" num="0041">Further, L-cysteine-producing ability of a bacterium can also be improved by enhancing the L-cysteine secretion system. The L-cysteine secretion system can be enhanced by enhancing expression of a gene coding for a protein involved in secretion of L-cysteine. Examples of the protein involved in secretion of L-cysteine include the YdeD protein encoded by the ydeD gene, the YfiK protein encoded by the <i>yfiK</i> gene, and the YeaS protein encoded by the <i>yeaS</i> gene. Therefore, by enhancing expression of the ydeD gene (<nplcit id="ncit0014" npl-type="s"><text>Dassler et al., Mol. Microbiol., 36, 1101-1112 (2000</text></nplcit>)), the <i>yfiK</i> gene (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0024" dnum="JP2004049237A"><text>2004-49237</text></patcit>) or the <i>yeaS</i> gene (European Patent Laid-open No. <patcit id="pcit0025" dnum="EP1016710A"><text>1016710</text></patcit>), L-cysteine-producing ability can be enhanced. Further, by introducing a mutation into the threonine residue of position 28, the phenylalanine residue of position 137, and/or the leucine residue of position 188 of the YeaS protein, the L-cysteine secretion system is also enhanced, and L-cysteine-producing ability can be enhanced (European Patent Laid-open No. <patcit id="pcit0026" dnum="EP2218729A"><text>2218729</text></patcit>). Specifically, a mutation for replacing the threonine residue at position 28 with asparagine residue, a mutation for replacing the phenylalanine residue at position 137 with serine, glutamine, alanine, histidine, cysteine or glycine residue, and/or a mutation for replacing the leucine residue at position 188 with glutamine residue in the YeaS protein is preferred (European Patent Laid-open No. <patcit id="pcit0027" dnum="EP2218729A"><text>2218729</text></patcit>).</p><p id="p0042" num="0042">Further, proteins suitable for secreting a substance showing cytotoxicity include those involved in secretion of L-cysteine. Therefore, by enhancing expression of a gene<!-- EPO <DP n="19"> --> coding for any one of them, the L-cysteine secretion system can be enhanced. For example, by increasing expression of the <i>mar</i> locus, <i>emr</i> locus, acr locus, <i>cmr</i> locus, <i>mex</i> gene, <i>bmr</i> gene or <i>qacA</i> gene (<patcit id="pcit0028" dnum="US5972663A"><text>U.S. Patent No. 5, 972, 663</text></patcit>), or <i>emrAB, emrKY, yojIH, acrEF, bcr</i> or <i>cusA</i> gene (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0029" dnum="JP2005287333A"><text>2005-287333</text></patcit>), which encode proteins suitable for secreting a substance showing cytotoxicity from cells, L-cysteine-producing ability can be enhanced.</p><p id="p0043" num="0043">Furthermore, the L-cysteine-producing ability can also be improved by enhancing the sulfate/thiosulfate transport system. The sulfate/thiosulfate transport system proteins are encoded by the <i>cysPTWAM</i> cluster genes (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0030" dnum="JP2005137369A"><text>2005-137369</text></patcit>, European Patent No. <patcit id="pcit0031" dnum="EP1528108A"><text>1528108</text></patcit>).</p><p id="p0044" num="0044">Further, L-cysteine-producing ability of a bacterium can be improved by reducing the activity of cysteine desulfhydrase, which contributes to decomposition of L-cysteine. As proteins having the cysteine desulfhydrase activity of <i>Escherichia coli,</i> cystathionine-β-lyase encoded by the <i>metC gene</i> (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0032" dnum="JP11155571A"><text>11-155571</text></patcit>, <nplcit id="ncit0015" npl-type="s"><text>Chandra et al., Biochemistry, 21, 3064-3069 (1982</text></nplcit>)), tryptophanase encoded by the <i>tnaA</i> gene (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0033" dnum="JP2003169668A"><text>2003-169668</text></patcit>, <nplcit id="ncit0016" npl-type="s"><text>Austin Newton et al., J. Biol. Chem., 240, 1211-1218 (1965</text></nplcit>)), O-acetylserine sulfhydrylase B encoded by the <i>cysM</i> gene (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0034" dnum="JP2005245311A"><text>2005-245311</text></patcit>) and MalY encoded by the <i>malY</i> gene (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0035" dnum="JP2005245311A"><text>2005-245311</text></patcit>) are known. The enzymatic activity can be reduced by the methods described later.</p><p id="p0045" num="0045">It is preferred that the L-cysteine-producing<!-- EPO <DP n="20"> --> bacterium has one or more of the following characteristics (1) to (3).
<ol><li>(1) The bacterium is modified so that the serine acetyltransferase activity is increased.</li><li>(2) The L-cysteine excretion system is enhanced.</li><li>(3) The bacterium is modified so that the 3-phosphoglycerate dehydrogenase activity is increased.</li></ol></p><p id="p0046" num="0046">Specific examples of L-cysteine-producing bacteria include, but not limited to, <i>Escherichia</i> bacteria such as the <i>E. coli</i> JM15 strain transformed with multiple kinds of <i>cysE</i> gene alleles encoding serine acetyltransferase (SAT) resistant to feedback inhibition (<patcit id="pcit0036" dnum="US6218168B"><text>U.S. Patent 6,218,168</text></patcit>), <i>E. coli</i> W3110 strain in which a gene encoding a protein suitable for secretion of a cytotoxic substance is overexpressed (<patcit id="pcit0037" dnum="US5972663A"><text>U.S. Patent No. 5,972,663</text></patcit>), <i>E. coli</i> in which cysteine desulfhydrase activity is decreased (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0038" dnum="JP11155571A"><text>11-155571</text></patcit>), and <i>E. coli</i> W3110 strain in which activity of the positive transcriptional control factor of the cysteine regulon encoded by the <i>cysB</i> gene is increased (<patcit id="pcit0039" dnum="WO0127307A"><text>WO01/27307</text></patcit>), <i>E.coli</i> having the plasmid pACYC-DES (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0040" dnum="JP2005137369A"><text>2005-137369</text></patcit> (<patcit id="pcit0041" dnum="US20050124049A1"><text>U.S. Patent Published Application No. 20050124049(A1</text></patcit>), European Patent Laid-open No. <patcit id="pcit0042" dnum="EP1528108A1"><text>1528108(A1</text></patcit>))) containing the <i>ydeD</i> gene, a mutant <i>cysE</i> gene, and a mutant serA5 gene, and so forth. pACYC-DES is a plasmid obtained by inserting the above three kinds of genes into pACYC184, and expression of each of the genes is controlled by the PompA promoter.</p><p id="p0047" num="0047">The ability to produce compound(s) biosynthesized from L-cysteine as a starting material, such as γ-glutamylcysteine, glutathione, cystathionine, homocysteine,<!-- EPO <DP n="21"> --> L-methionine, and S-adenosylmethionine, can also be imparted or enhanced by enhancing activity of an enzyme of the biosynthesis system of an objective compound, or reducing activity of an enzyme of a pathway branching from biosynthesis system of the objective compound or an enzyme that decomposes the objective compound.</p><p id="p0048" num="0048">For example, γ-glutamylcysteine-producing ability can be enhanced by enhancing the γ-glutamylcysteine synthetase activity, and/or reducing the glutathione synthetase activity. Further, glutathione-producing ability can be imparted or enhanced by enhancing the γ-glutamylcysteine synthetase activity and/or the glutathione synthetase activity. Further, by using a mutant γ-glutamylcysteine synthetase resistant to feedback inhibition by glutathione, the ability to produce γ-glutamylcysteine or glutathione can be enhanced. Production of glutathione is described in detail in the overview of Li et al. (<nplcit id="ncit0017" npl-type="s"><text>Yin Li, Gongyuan Wei, Jian Chen, Appl. Microbiol. Biotechnol., 66:233-242 (2004</text></nplcit>)).</p><p id="p0049" num="0049">L-methionine-producing ability can be imparted or enhanced by imparting L-threonine auxotrophy or norleucine resistance (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0043" dnum="JP2000139471A"><text>2000-139471</text></patcit>). In E. <i>coli,</i> the genes of the enzymes involved in the biosynthesis of L-threonine exist as the threonine operon <i>(thrABC),</i> and an L-threonine auxotrophic strain that has lost the biosynthesis ability for L-homoserine and the following compounds can be obtained by, for example, deleting the <i>thrBC</i> moiety. In a norleucine resistant strain, the S-adenosylmethionine synthetase activity is attenuated, and L-methionine-producing ability is imparted or enhanced. In <i>E. coli,</i> S-adenosylmethionine synthetase is encoded by the <i>metK</i> gene<i>.</i> L-methionine-producing<!-- EPO <DP n="22"> --> ability can also be imparted or enhanced by deleting the methionine repressor or enhancing activity of an enzyme involved in the L-methionine biosynthesis, such as homoserine transsuccinylase, cystathionine γ-synthase and aspartokinase-homoserine dehydrogenase II (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0044" dnum="JP2000139471A"><text>2000-139471</text></patcit>). In <i>E. coli,</i> the methionine repressor is encoded by the <i>metJ</i> gene, homoserine transsuccinylase is encoded by the <i>metA</i> gene, cystathionine γ-synthase is encoded by the <i>metB</i> gene, and aspartokinase-homoserine dehydrogenase II is encoded by the <i>metL</i> gene. Further, by using a mutant homoserine transsuccinylase resistant to feedback inhibition by L-methionine, L-methionine-producing ability can also be imparted or enhanced (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0045" dnum="JP2000139471A"><text>2000-139471</text></patcit>, <patcit id="pcit0046" dnum="US20090029424A"><text>U.S. Patent Published Application No. 20090029424</text></patcit>). Because L-methionine is biosynthesized via L-cysteine as an intermediate, L-methionine-producing ability can also be improved by improving L-cysteine-producing ability (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0047" dnum="JP2000139471A"><text>2000-139471</text></patcit>, <patcit id="pcit0048" dnum="US20080311632A"><text>U.S. Patent Published Application No. 20080311632</text></patcit>). Therefore, for imparting or enhancing L-methionine-producing ability, it is also effective to impart or enhance L-cysteine-producing ability.</p><p id="p0050" num="0050">Specific examples of L-methionine-producing bacteria include <i>E. coli</i> strains such as AJ11539 (NRRL B-12399), AJ11540 (NRRL B-12400), AJ11541 (NRRL B-12401), AJ11542 (NRRL B-12402) (British Patent No. <patcit id="pcit0049" dnum="GB2075055A"><text>2075055</text></patcit>), 218 strain resistant to norleucine, which is an analogue of L-methionine (VKPM B-8125, Russian Patent No. <patcit id="pcit0050" dnum="RU2209248"><text>2209248</text></patcit>), and 73 strain (VKPM B-8126, Russian Patent No. <patcit id="pcit0051" dnum="RU2215782"><text>2215782</text></patcit>).</p><p id="p0051" num="0051">Further, as an L-methionine-producing bacterium,<!-- EPO <DP n="23"> --> AJ13425 (FERM P-16808, Japanese Patent Laid-open (Kokai) No. 2000-139471) derived from the <i>E. coli</i> W3110 can also be used. AJ13425 is an L-threonine auxotrophic strain in which the methionine repressor is deleted, intracellular S-adenosylmethionine synthetase activity is attenuated, and intracellular homoserine transsuccinylase activity, cystathionine γ-synthase activity, and aspartokinase-homoserine dehydrogenase II activity are enhanced. AJ13425 was deposited on May 14, 1998 at the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository, Address: Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan), and assigned an accession number of FERM P-16808.</p><p id="p0052" num="0052">Because cystathionine and homocysteine are intermediates of the L-methionine biosynthesis pathway, it is effective to partially use the aforementioned methods for enhancing L-methionine-producing ability for enhancing abilities to produce these substances. As specific methods for enhancing cystathionine-producing ability, there are known a method using a methionine-auxotrophic mutant strain (Japanese Patent Application No. <patcit id="pcit0052" dnum="JP2003010654A"><text>2003-010654</text></patcit>) and a method adding cysteine (or raw material for biosynthesis thereof) and/or homoserine (or raw material for biosynthesis thereof) to a fermentation medium (Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0053" dnum="JP2005168422A"><text>2005-168422</text></patcit>). Since homocysteine is produced by using cystathionine as a precursor, the aforementioned methods for enhancing cystathionine-producing ability are also effective for enhancing homocysteine-producing ability.<!-- EPO <DP n="24"> --></p><p id="p0053" num="0053">Further, the ability to produce compound(s) biosynthesized by using L-methionine as a starting material, such as S-adenosylmethionine, can also be imparted or enhanced by enhancing activity of an enzyme of the biosynthesis system of an objective compound, or reducing activity of an enzyme of a pathway branching from the biosynthesis pathway of the objective compound or an enzyme that decomposes the objective compound. For example, S-adenosylmethionine-producing ability can be imparted or enhanced by enhancing the methionine adenosyltransferase activity (European Patent Laid-open Nos. <patcit id="pcit0054" dnum="EP0647712A"><text>0647712</text></patcit> and <patcit id="pcit0055" dnum="EP1457569A"><text>1457569</text></patcit>) or enhancing the secretion factor MdfA encoded by the <i>mdfA</i> gene (<patcit id="pcit0056" dnum="US7410789B"><text>U.S. Patent No. 7,410,789</text></patcit>).</p><p id="p0054" num="0054">Hereafter, methods for reducing the enzymatic activity of cysteine desulfhydrase or the like will be described. In the present invention, the expression "enzymatic activity is reduced" means that the enzymatic activity is decreased compared with that of a non-modified strain such as a wild-type strain or a parent strain, and includes a case where the activity has completely disappeared. The enzymatic activity is preferably reduced to, for example, 75% or less, 50% or less, 25% or less, or 10% or less compared with that of a non-modified strain, and the complete disappearance of the activity is particularly preferred. Depending on the type of enzyme, it can also be rather preferable not to completely eliminate the enzymatic activity.</p><p id="p0055" num="0055">A modification for reducing the enzymatic activity can be attained by, for example, reducing expression of a gene coding for the objective enzyme. Expression of a gene<!-- EPO <DP n="25"> --> can be reduced by, for example, modifying an expression control sequence, such as promoter and SD sequence, of the gene. When an expression control sequence is modified, one or more nucleotides, more preferably two or more nucleotides, particularly preferably three or more nucleotides, of the expression control sequence are modified. Further, a part or all of the expression control sequence can be deleted. Further, expression of a gene can also be reduced by expressing an antisense RNA.</p><p id="p0056" num="0056">Further, a modification for reducing the enzymatic activity can also be attained by, for example, deleting a part or all of a coding region of a gene coding for an objective enzyme on a chromosome. Further, the whole gene including the sequences upstream and downstream of the gene on a chromosome can be deleted. The region to be deleted can be an N-terminus region, an internal region or a C-terminus region, so long as the enzymatic activity can be reduced. Deletion of a longer region can usually more surely inactivate a gene. Furthermore, it is preferred that reading frames upstream and downstream of the region to be deleted are not the same.</p><p id="p0057" num="0057">Further, a modification for reducing the enzymatic activity can also be attained by introducing a mutation for amino acid substitution (missense mutation), a stop codon (nonsense mutation), or a frame shift mutation which adds or deletes one or two nucleotides into a coding region of a gene coding for the objective enzyme on a chromosome (<nplcit id="ncit0018" npl-type="s"><text>Journal of Biological Chemistry, 272:8611-8617 (1997</text></nplcit>); <nplcit id="ncit0019" npl-type="s"><text>Proceedings of the National Academy of Sciences, USA, 95 5511-5515 (1998</text></nplcit>); <nplcit id="ncit0020" npl-type="s"><text>Journal of Biological Chemistry, 266, 20833-20839 (1991</text></nplcit>)).<!-- EPO <DP n="26"> --></p><p id="p0058" num="0058">Further, a modification for reducing the enzymatic activity can also be attained by inserting another sequence into a coding region of a gene coding for an objective enzyme on a chromosome. Such a sequence can be inserted into any region of the gene, and insertion of a longer sequence can more surely inactivate the objective gene. It is preferred that reading frames upstream and downstream of the insertion site are not the same. The other sequence is not particularly limited so long as a sequence which decreases or deletes function of the encoded protein is chosen, and examples include a marker gene such as antibiotic resistance genes, a gene useful for L-cysteine production, and so forth.</p><p id="p0059" num="0059">A gene on a chromosome can be modified as described above by, for example, preparing a deletion-type gene of the gene, in which a partial sequence of the gene is deleted so that the deletion-type gene does not produce a protein that can normally function, and then transforming a bacterium with a recombinant DNA containing the deletion-type gene to cause homologous recombination between the deletion-type gene and the native gene on the chromosome, which results in substitution of the deletion-type gene for the native gene on the chromosome. The above operation can be made easier by introducing a marker gene suitable for a characteristic of the host such as auxotrophy into the recombinant DNA. The protein encoded by the deletion-type gene has a conformation different from that of the wild-type protein, even if it is even produced, and thus the function is reduced or deleted. Such gene disruption based on gene substitution utilizing homologous recombination has already been established, and examples include the method<!-- EPO <DP n="27"> --> called Red-driven integration (<nplcit id="ncit0021" npl-type="s"><text>Datsenko, K.A., and Wanner, B.L., Proc. Natl. Acad. Sci. USA, 97:6640-6645 (2000</text></nplcit>)), methods using a linear DNA such as the method of utilizing Red driven integration in combination with an excision system derived from λ phage (<nplcit id="ncit0022" npl-type="s"><text>Cho, E.H., Gumport, R.I., Gardner, J.F., J. Bacteriol., 184:5200-5203 (2002</text></nplcit>)) (refer to <patcit id="pcit0057" dnum="WO2005010175A"><text>WO2005/010175</text></patcit>), methods using a plasmid containing a temperature sensitive replication origin, methods using a plasmid capable of conjugative transfer, methods utilizing a suicide vector without a replication origin in a host (<patcit id="pcit0058" dnum="US6303383B"><text>U.S. Patent No. 6,303,383</text></patcit>, Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0059" dnum="JP5007491A"><text>05-007491</text></patcit>), and so forth.</p><p id="p0060" num="0060">Further, a modification for reducing the enzymatic activity can also be attained by, for example, mutagenesis. Examples of mutagenesis include exposure to UV irradiation or a treatment with a mutagen used for usual mutagenesis such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS) and methyl methanesulfonate (MMS).</p><p id="p0061" num="0061">Decrease of the enzymatic activity can be confirmed by measuring the enzymatic activity. The cysteine desulfhydrase activity can be measured by the method described in Japanese Patent Laid-open (Kokai) No. <patcit id="pcit0060" dnum="JP2002233384A"><text>2002-233384</text></patcit>.</p><p id="p0062" num="0062">Decrease of the transcription amount of an objective gene can be confirmed by comparing the amount of mRNA transcribed from the gene with that of a non-modified strain. Examples of method for evaluating amount of mRNA include Northern hybridization, RT-PCR, and so forth (<nplcit id="ncit0023" npl-type="b"><text>Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 2001</text></nplcit>).<!-- EPO <DP n="28"> --></p><p id="p0063" num="0063">Decrease of the amount of an objective protein can be confirmed by Western blotting using an antibody (<nplcit id="ncit0024" npl-type="b"><text>Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 2001</text></nplcit>).</p><heading id="h0013">Increase of L-aspartate-α-decarboxylase activity</heading><p id="p0064" num="0064">The bacterium of the present invention is modified so that the L-aspartate-α-decarboxylase activity is increased. The bacterium of the present invention can be obtained by modifying a bacterium belonging to the family <i>Enterobacteriaceae</i> and having L-cysteine-producing ability such as those mentioned above so that the L-aspartate-α-decarboxylase activity is increased. Alternatively, after a bacterium is modified so that the L-aspartate-α-decarboxylase activity is increased, L-cysteine-producing ability can also be imparted or enhanced.</p><p id="p0065" num="0065">In the present invention, the L-aspartate-α-decarboxylase activity means the activity for catalyzing the reaction of decarboxylating L-aspartic acid thereby to generate β-alanine. In the present invention, a protein having the L-aspartate-α-decarboxylase activity is called L-aspartate-α-decarboxylase. It is expected that increase of the L-aspartate-α-decarboxylase activity increases the production amount of pantothenic acid, which is biosynthesized by using β-alanine as a metabolic intermediate.</p><p id="p0066" num="0066">The expression "L-aspartate-α-decarboxylase activity is increased" means that the L-aspartate-α-decarboxylase activity is increased compared with that of a non-modified strain such as a wild strain or a parent strain. Although<!-- EPO <DP n="29"> --> the degree of increase of the L-aspartate-α-decarboxylase activity is not particularly limited so long as the L-aspartate-α-decarboxylase activity is increased compared with that of a non-modified strain, the L-aspartate-α-decarboxylase activity is increased to preferably 150% or more, more preferably 200% or more, still more preferably 300% or more, compared with that of a non-modified strain. Furthermore, the case where the "L-aspartate-α-decarboxylase activity is increased" includes not only a case where L-aspartate-α-decarboxylase activity is increased in a strain inherently having the L-aspartate-α-decarboxylase activity, but also a case where L-aspartate-α-decarboxylase activity is imparted to a strain not inherently having the L-aspartate-α-decarboxylase activity. Moreover, so long as the L-aspartate-α-decarboxylase activity is increased as a result, L-aspartate-α-decarboxylase that is inherently possessed by a bacterium can be attenuated and/or deleted, and then an appropriate L-aspartate-α-decarboxylase can be introduced.</p><p id="p0067" num="0067">A modification for increasing the L-aspartate-α-decarboxylase activity can be attained by, for example, enhancing expression of a gene coding for L-aspartate-α-decarboxylase.</p><p id="p0068" num="0068">Enhancement of expression of a gene can be attained by, for example, increasing the copy number of the gene.</p><p id="p0069" num="0069">The copy number of an objective gene can be increased by introducing the gene into a chromosome. A gene can be introduced into a chromosome by, for example, using homologous recombination. For example, a large number of copies of a gene can be introduced into a chromosome by<!-- EPO <DP n="30"> --> performing homologous recombination for a sequence that exists on a chromosome in a large copy number as a target. Examples of sequence existing on a chromosome in a large copy number include, but not limited to, repetitive DNA and inverted repeats existing at the both ends of a transposon. An objective gene can be ligated on the side of an L-aspartate-α-decarboxylase gene on a chromosome in tandem or can also be introduced into an unnecessary gene on a chromosome so that the objective gene overlaps with the unnecessary gene. Such gene introduction can be attained by using a temperature sensitive vector or by using an integration vector. Alternatively, as disclosed in <patcit id="pcit0061" dnum="US5595889A"><text>U.S. Patent No. 5,595,889</text></patcit>, it is also possible to incorporate an objective gene into a transposon, and allow it to be transferred to a chromosomal DNA to introduce a large number of copies of the gene. As the transposon, for example, Mu, Tn10 and Tn5 can be used. Whether an objective gene has been introduced into a chromosome can be confirmed by Southern hybridization using a part of the objective gene as a probe.</p><p id="p0070" num="0070">Further, the copy number of an objective gene can also be increased by introducing a vector containing the gene into a host bacterium. For example, the copy number of an objective gene can be increased by ligating a DNA fragment containing the objective gene with a vector that functions in the host bacterium to construct an expression vector of the objective gene, and transforming the host bacterium with the expression vector. As the vector, a vector autonomously replicable in the cell of the host bacterium can be used. The vector is preferably a multicopy vector. Further, the vector preferably has a marker such as an antibiotic resistance gene for selection of the<!-- EPO <DP n="31"> --> transformants. Examples of vector autonomously replicable in <i>Escherichia coli</i> cells include pUC19, pUC18, pHSG299, pHSG399, pHSG398, pACYC184, pBR322, pSTV29 (all of these are available from Takara Bio), pMW219 (NIPPON GENE), pTrc99A (Pharmacia), pPROK series vectors (Clontech), pKK233-2 (Clontech), pET series vectors (Novagen), pQE series vectors (QIAGEN), broad host spectrum vector RSF1010, and so forth.</p><p id="p0071" num="0071">Further, expression of a gene can be enhanced by improving the transcription efficiency of the gene. The transcription efficiency of a gene can be improved by, for example, substituting a stronger promoter for the promoter of the gene on the chromosome. The "stronger promoter" means a promoter providing improved transcription of a gene compared with the natively existing wild-type promoter. As a stronger promoter, for example, known high expression promoters, such as T7 promoter, trp promoter, lac promoter, tac promoter, and PL promoter, can be used. Further, as the stronger promoter, a highly-active type of a usual promoter can be obtained by using various reporter genes. For example, by making the -35 and -10 regions in a promoter region closer to the consensus sequence, activity of the promoter can be enhanced (International Patent Publication <patcit id="pcit0062" dnum="WO0018935A"><text>WO00/18935</text></patcit>). Methods for evaluating the strength of promoters and examples of strong promoter are described in the paper of <nplcit id="ncit0025" npl-type="s"><text>Goldstein et al. (Prokaryotic Promoters in Biotechnology, Biotechnol. Annu. Rev., 1, 105-128 (1995</text></nplcit>)), and so forth.</p><p id="p0072" num="0072">Further, expression of a gene can also be enhanced by improving the translation efficiency of the gene. The translation efficiency of a gene can be improved by, for<!-- EPO <DP n="32"> --> example, replacing the SD sequence (also referred to as ribosome binding site (RBS)) on a chromosome with a stronger SD sequence. The "stronger SD sequence" means a SD sequence that provides improved translation of mRNA compared with the natively existing wild-type SD sequence. Examples of the stronger SD sequence include, for example, RBS of the gene 10 derived from phage T7 (<nplcit id="ncit0026" npl-type="s"><text>Olins P.O. et al, Gene, 1988, 73, 227-235</text></nplcit>). Furthermore, it is known that substitution, insertion, or deletion of several nucleotides in a spacer region between RBS and the start codon, especially in a sequence immediately upstream of the start codon (5'-UTR), significantly affects the stability and translation efficiency of mRNA, and translation efficiency of a gene can also be improved by modifying them.</p><p id="p0073" num="0073">In the present invention, sites affecting gene expression, such as promoter, SD sequence and spacer region between RBS and the start codon, are also generically called "expression control regions". An expression control region can be determined by using a promoter-search vector or gene analysis software such as GENETYX. Such expression control regions can be modified by, for example, a method using a temperature sensitive vector or the Red driven integration method (<patcit id="pcit0063" dnum="WO2005010175A"><text>WO2005/010175</text></patcit>).</p><p id="p0074" num="0074">Further, expression of an objective gene can also be enhanced by amplifying a regulator that increases expression of the gene, or deleting or attenuating a regulator that reduces expression of the gene. Examples of the regulator include, for example, those belonging to the LysR family, and so forth, and they can be found by using a database, such as EcoCyc (http://ecocyc.org/), or the like. A regulator can be modified with monitoring the increase of<!-- EPO <DP n="33"> --> the transcription amount of the objective gene or the increase of the amount of the objective protein as an index.</p><p id="p0075" num="0075">Such methods for enhancing gene expression as mentioned above can be used independently or in an arbitrary combination.</p><p id="p0076" num="0076">Further, a modification that increases the L-aspartate-α-decarboxylase activity can also be attained by, for example, enhancing specific activity of the L-aspartate-α-decarboxylase. An L-aspartate-α-decarboxylase showing enhanced specific activity can be obtained by, for example, searching various bacteria. Further, a highly-active type variant of an existing L-aspartate-α-decarboxylase can also be obtained by introducing a mutation into the existing L-aspartate-α-decarboxylase. Enhancement of specific activity can be independently used, or can be used in an arbitrary combination with such methods for enhancing gene expression as mentioned above.</p><p id="p0077" num="0077">The method of the transformation is not particularly limited, and conventionally known methods can be used. There can be used, for example, methods of treating recipient cells with calcium chloride so as to increase permeability thereof for DNA, which has been reported for <i>Escherichia coli</i> K-12 strain (<nplcit id="ncit0027" npl-type="s"><text>Mandel, M. and Higa, A., J. Mol. Biol., 53:159-162 (1970</text></nplcit>)), and preparing competent cells from cells which are at the growth phase, followed by transformation with DNA, which has been reported for <i>Bacillus subtilis</i> (<nplcit id="ncit0028" npl-type="s"><text>Duncan, C.H., Wilson, G.A. and Young, F.E., Gene, 1, 153 (1977</text></nplcit>)). Alternatively, there can also be used a method of making DNA-recipient cells into protoplasts or spheroplasts, which can easily take up<!-- EPO <DP n="34"> --> recombinant DNA, followed by introducing a recombinant DNA into the cells, which is known to be applicable to <i>Bacillus subtilis,</i> actinomycetes and yeasts (<nplcit id="ncit0029" npl-type="s"><text>Chang, S. and Choen, S.N., 1979, Molec. Gen. Genet., 168:111 (1979</text></nplcit>); <nplcit id="ncit0030" npl-type="s"><text>Bibb, M.J., Ward, J.M. and Hopwood, O.A., Nature, 274, 398 (1978</text></nplcit>); <nplcit id="ncit0031" npl-type="s"><text>Hinnen, A., Hicks, J.B. and Fink, G.R., Proc. Natl. Acad. Sci. USA, 75, 1929 (1978</text></nplcit>)).</p><p id="p0078" num="0078">Increase of an objective enzymatic activity can be confirmed by measuring the enzymatic activity. The L-aspartate-α-decarboxylase activity can be measured by the method described in Non-patent document 4 (<nplcit id="ncit0032" npl-type="s"><text>Dusch N. et al., Appl. Environ. Microbiol., 1999 Apr;65(4):1530-9</text></nplcit>).</p><p id="p0079" num="0079">Increase of the transcription amount of an objective gene can be confirmed by comparing amount of mRNA transcribed from the gene with that of a wild-type strain or a non-modified strain. Examples of method for evaluating amount of mRNA include Northern hybridization, RT-PCR, and so forth (<nplcit id="ncit0033" npl-type="b"><text>Molecular Cloning, Cold spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001</text></nplcit>).</p><p id="p0080" num="0080">Increase of the amount of an objective protein can be confirmed by Western blotting using an antibody (<nplcit id="ncit0034" npl-type="b"><text>Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001</text></nplcit>).</p><p id="p0081" num="0081">Objects of such methods for enhancing expression of a gene or specific activity of an enzyme as mentioned above are not limited to L-aspartate-α-decarboxylase and a gene coding for it, but they can be similarly applied to arbitrary enzymes such as SAT, genes coding for them, and so forth.<!-- EPO <DP n="35"> --></p><p id="p0082" num="0082">L-aspartate-α-decarboxylase is generally encoded by the <i>panD</i> gene. The protein encoded by the <i>panD</i> gene is also called PanD protein. The <i>panD</i> gene of the <i>Escherichia coli</i> K12 MG1655 strain corresponds to a complementary sequence of the sequence of positions 146314 to 146694 in the genome sequence registered at the NCBI database as GenBank accession NC_000913 (VERSION NC_000913.2 GI: 49175990). The <i>panD</i> gene of the <i>Escherichia coli</i> K12 MG1655 strain is synonymous with ECK0130 or JW0127. Furthermore, the PanD protein of the <i>Escherichia coli</i> K12 MG1655 strain is registered as GenBank accession NP_414673 (version NP_414673.1 GI: 16128124, locus_tag="b0131"). The nucleotide sequences of the <i>panD</i> gene of the MG1655 strain and the amino acid sequence of the protein encoded by the gene are shown as SEQ ID NOS: 7 and 8, respectively. The nucleotide sequences of the <i>panD</i> gene of the <i>Pantoea ananatis</i> SC17 strain and the amino acid sequence of the protein encoded by the gene are shown as SEQ ID NOS: 9 and 10, respectively. The nucleotide sequences of the <i>panD</i> gene of the <i>Corynebacterium glutamicum</i> 2256 strain and the amino acid sequence of the protein encoded by the gene are shown as SEQ ID NOS: 11 and 12, respectively. The nucleotide sequences of the <i>panD</i> gene of the <i>Bacillus subtilis</i> 168 strain and the amino acid sequence of the protein encoded by the gene are shown as SEQ ID NOS: 13 and 14, respectively.</p><p id="p0083" num="0083">Since the nucleotide sequence of the <i>panD</i> gene can differ depending on the genus, species or strain to which the bacterium belongs, the <i>panD</i> gene to be modified so that the L-aspartate-α-decarboxylase activity is increased can be a variant of the nucleotide sequence shown as SEQ ID NO:<!-- EPO <DP n="36"> --> 7, 9, 11, or 13, so long as it codes for a protein having the L-aspartate-α-decarboxylase activity. A variant of the <i>panD</i> gene can be searched for by using BLAST (http://blast.genome.jp/) or the like with referring to, for example, the nucleotide sequence of SEQ ID NO: 7, 9, 11, or 13. Furthermore, the variant of the <i>panD</i> gene includes homologues of the gene. Examples of the homologues of the <i>panD</i> gene include genes that can be amplified by PCR using a chromosome of such a microorganism as bacteria belonging to the family <i>Enterobacteriaceae</i> and coryneform bacteria as a template and synthetic oligonucleotides prepared on the basis of the nucleotide sequence of SEQ ID NO: 7, 9, 11, or 13.</p><p id="p0084" num="0084">Furthermore, examples of <i>panD</i> gene homologue of bacteria other than the aforementioned bacteria include <i>panD</i> genes of the following bacteria. Identities (%) of the PanD proteins encoded by the <i>panD</i> gene homologues of the bacteria relative to the PanD protein of the <i>Escherichia coli</i> K12 strain (SEQ ID NO: 8) determined by using BLAST are shown in the parentheses. The nucleotide sequences of these genes and the amino acid sequences encoded by them are shown as SEQ ID NOS: 15 to 60. In addition, the <i>panD</i> gene can be a variant of these homologues, so long as the variant codes for a protein having the L-aspartate-α-decarboxylase activity.<br/>
<i>Arthrobacter aurescens</i> ATCC BAA-1386 (54)<br/>
<i>Bacteroides fragilis</i> ATCC 25285 (44)<br/>
<i>Bacteroides vulgatus</i> ATCC 8482 (48)<br/>
<i>Brevibacterium lactofermentum</i> ATCC 13869 (43)<br/>
<i>Chlorobium tepidum</i> ATCC 49652 (47)<br/>
<i>Citrobacter koseri</i> ATCC BAA-895 (96)<br/>
<i>Clavibacter michiganensis</i> NCPPB 382 (51)<br/>
<!-- EPO <DP n="37"> --><i>Corynebacterium jeikeium</i> NCTC 11915 (48)<br/>
<i>Cytophaga hutchinsonii</i> ATCC 33406 (44)<br/>
<i>Enterobacter sakazakii</i> ATCC BAA-894 (90)<br/>
<i>Flavobacterium johnsoniae</i> ATCC 17061 (45)<br/>
<i>Flavobacterium psychrophilum</i> ATCC 49511 (44)<br/>
<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i> MGH78578 ATCC 700721 (89)<br/>
<i>Methylophilus methylotrophus</i> ATCC 53528 (53)<br/>
<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> ATCC 19851 (50)<br/>
<i>Parabacteroides distasonis</i> ATCC 8503 (48)<br/>
<i>Porphyromonas gingivalis</i> ATCC 53978 (45)<br/>
<i>Rhodococcus</i> sp. (49)<br/>
<i>Saccharopolyspora erythraea</i> ATCC 11635 (51)<br/>
<i>Salinibacter ruber</i> ATCC BAA-605 (44)<br/>
<i>Salmonella enterica</i> subsp. <i>arizonae</i> serovar 62 ATCC BAA-731 (96)<br/>
<i>Streptomyces coelicolor</i> ATCC 10147 (51)<br/>
<i>Thermobifida fusca</i> ATCC 27730 (49)</p><p id="p0085" num="0085">The <i>panD</i> gene can be a gene coding for a protein having the amino acid sequence of the PanD protein as mentioned above, such as the amino acid sequence shown as SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60, but including substitution, deletion, insertion, addition or the like of one or several amino acid residues at one or several positions, so long as it codes for a protein having the L-aspartate-α-decarboxylase activity. Although the number meant by the term "one or several" can differ depending on positions in the three-dimensional structure of the protein or types of amino acid residues, specifically, it is preferably 1 to 20, more preferably 1 to 10, still more preferably 1 to 5. The above<!-- EPO <DP n="38"> --> substitution, deletion, insertion, or addition of one or several amino acid residues is a conservative mutation that maintains normal function of the protein. The conservative mutation is typically a conservative substitution. The conservative substitution is a mutation wherein substitution takes place mutually among Phe, Trp and Tyr, if the substitution site is an aromatic amino acid; among Leu, Ile and Val, if it is a hydrophobic amino acid; between Gln and Asn, if it is a polar amino acid; among Lys, Arg and His, if it is a basic amino acid; between Asp and Glu, if it is an acidic amino acid; and between Ser and Thr, if it is an amino acid having hydroxyl group. Specific examples of conservative substitutions include: substitution of Ser or Thr for Ala; substitution of Gln, His or Lys for Arg; substitution of Glu, Gln, Lys, His or Asp for Asn; substitution of Asn, Glu or Gln for Asp; substitution of Ser or Ala for Cys; substitution of Asn, Glu, Lys, His, Asp or Arg for Gln; substitution of Gly, Asn, Gln, Lys or Asp for Glu; substitution of Pro for Gly; substitution of Asn, Lys, Gln, Arg or Tyr for His; substitution of Leu, Met, Val or Phe for Ile; substitution of Ile, Met, Val or Phe for Leu; substitution of Asn, Glu, Gln, His or Arg for Lys; substitution of Ile, Leu, Val or Phe for Met; substitution of Trp, Tyr, Met, Ile or Leu for Phe; substitution of Thr or Ala for Ser; substitution of Ser or Ala for Thr; substitution of Phe or Tyr for Trp; substitution of His, Phe or Trp for Tyr; and substitution of Met, Ile or Leu for Val. The above-mentioned amino acid substitution, deletion, insertion, addition, inversion etc. can be a result of a naturally-occurring mutation (mutant or variant) due to an individual difference, a difference of species, or the like of a bacterium from which the gene is derived.<!-- EPO <DP n="39"> --></p><p id="p0086" num="0086">Furthermore, the gene having such a conservative mutation as mentioned above can be a gene coding for a protein showing a homology of 80% or more, preferably 90% or more, more preferably 95% or more, still more preferably 97% or more, particularly preferably 99% or more, to the total amino acid sequence of the PanD protein, such as the total sequence of the amino acid sequence of SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60, and having the L-aspartate-α-decarboxylase activity. In this specification, "homology" can mean "identity".</p><p id="p0087" num="0087">Further, the <i>panD</i> gene can be a DNA that is able to hybridize with a probe that can be prepared from a known gene sequence, for example, a complementary sequence of the nucleotide sequence of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, or 59, under stringent conditions, and coding for a protein having the L-aspartate-α-decarboxylase activity. The "stringent conditions" refer to conditions under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed. Examples of the stringent conditions include those under which highly homologous DNAs hybridize to each other, for example, DNAs not less than 80% homologous, preferably not less than 90% homologous, more preferably not less than 95% homologous, still more preferably not less than 97% homologous, particularly preferably not less than 99% homologous, hybridize to each other, and DNAs less homologous than the above do not hybridize to each other, or conditions of washing of typical Southern hybridization, i.e., conditions of washing once, preferably 2 or 3 times, at a salt<!-- EPO <DP n="40"> --> concentration and temperature corresponding to 1 x SSC, 0.1% SDS at 60°C, preferably 0.1 x SSC, 0.1% SDS at 60°C, more preferably 0.1 x SSC, 0.1% SDS at 68°C.</p><p id="p0088" num="0088">The probe can be a part of the complimentary sequence of the gene. Such a probe can be prepared by PCR using oligonucleotides prepared on the basis of a known gene sequence as primers and a DNA fragment containing the nucleotide sequence as a template. For example, when a DNA fragment having a length of about 300 bp is used as the probe, the washing conditions of the hybridization can be, for example, 50°C, 2 x SSC and 0.1% SDS.</p><p id="p0089" num="0089">The aforementioned explanation of the variants of genes and proteins are also similarly applied to enzymes such as serine acetyltransferase and 3-phosphoglycerate dehydrogenase, the YdeD protein, and the genes coding for them.</p><p id="p0090" num="0090">Alignment of the amino acid sequences of the PanD proteins derived from various bacteria is shown in <figref idrefs="f0001 f0002 f0003 f0004">Fig. 1</figref>. As already reported so far, the PanD proteins contain commonly conserved regions (<nplcit id="ncit0035" npl-type="s"><text>Armando Albert et al., 1998, Nature Structural Biology, Volume 5, No. 4:289-293</text></nplcit>). Therefore, those conserved regions are preferably conserved in the PanD protein.</p><p id="p0091" num="0091">Specifically, it is preferred that the glycine residue of position 24 and the serine residue of position 25 are conserved in the PanD protein. The PanD protein is divided into the α subunit and β subunit between the glycine residue of position 24 and the serine residue of position 25. These amino acid residues were commonly<!-- EPO <DP n="41"> --> conserved in the PanD proteins of all the species mentioned in the alignment (<figref idrefs="f0001 f0002 f0003 f0004">Fig. 1</figref>).</p><p id="p0092" num="0092">Furthermore, it is preferred that the lysine residue of position 9, the histidine residue of position 11, the threonine residue of position 57, and the tyrosine residue of position 58 are conserved. These amino acid residues are estimated to constitute a pocket on the basis of the three-dimensional structure, and it is thought that they contribute to the L-aspartate-α-decarboxylase activity. These amino acid residues were commonly conserved in the PanD proteins of all the species mentioned in the alignment (<figref idrefs="f0001 f0002 f0003 f0004">Fig. 1</figref>).</p><p id="p0093" num="0093">Furthermore, it is preferred that one or more residues selected from the valine residue of position 15, the threonine residue of position 16, the leucine residue of position 20, the tyrosine residue of position 22, the aspartic acid residue of position 29, the glutamic acid residue of position 42, the asparagine residue of position 51, the glycine residue of position 52, the arginine residue of position 54, the isoleucine residue of position 60, the asparagine residue of position 72, the glycine residue of position 73, the alanine residue of position 74, the alanine residue of position 75, the alanine residue of position 76, the aspartic acid residue of position 83, and the isoleucine residue of position 86 are conserved, and it is more preferred that all of these residues are conserved. These amino acid residues substantially commonly conserved in the PanD proteins mentioned in the alignment (<figref idrefs="f0001 f0002 f0003 f0004">Fig. 1</figref>).</p><p id="p0094" num="0094">Each of the aforementioned amino acid residues refers to an amino acid residue corresponding to each of the<!-- EPO <DP n="42"> --> positions in SEQ ID NO: 8. That is, positions of the aforementioned amino acid residues represent relative positions, and can be changed by deletion, insertion, addition, or the like of amino acid residues. For example, the "serine residue of position 25" means the serine residue corresponding to position 25 in SEQ ID NO: 8. When one amino acid residue on the N-terminus side of position 25 is deleted, the 24th serine residue from the N-terminus (the methionine residue encoded by the start codon is also counted) shall be the "serine residue of position 25". When one amino acid residue is inserted on the N-terminus side of position 25, the 26th serine residue from the N-terminus shall be the "serine residue of position 25". Furthermore, for example, the expression "the serine residue of position 25 is conserved" in the PanD protein means that an amino acid residue corresponding to position 25 in SEQ ID NO: 8 is a serine residue in that PanD protein. The same holds for the other amino acid residues.</p><heading id="h0014">&lt;2&gt; Method for producing L-cysteine, related substance thereof, or a mixture thereof of the present invention</heading><p id="p0095" num="0095">By culturing the bacterium of the present invention obtained as described above in a medium and collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium, these compounds can be produced. Examples of the related substance of L-cysteine include S-sulfocysteine, thiazolidine derivatives, hemithioketals corresponding to the thiazolidine derivatives, L-methionine, S-adenosylmethionine, and so forth mentioned above.</p><p id="p0096" num="0096">Examples of the medium to be used include ordinary media containing a carbon source, nitrogen source, sulfur source, inorganic ions, and other organic components as<!-- EPO <DP n="43"> --> required.</p><p id="p0097" num="0097">Examples of the carbon source include saccharides such as glucose, fructose, sucrose, molasses, and starch hydrolysate, and organic acids such as fumaric acid, citric acid, and succinic acid.</p><p id="p0098" num="0098">Examples of the nitrogen source include inorganic ammonium salts such as ammonium sulfate, ammonium chloride and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, and aqueous ammonia.</p><p id="p0099" num="0099">Examples of the sulfur source include inorganic sulfur compounds such as sulfates, sulfites, hyposulfites, thiosulfates, and sulfides.</p><p id="p0100" num="0100">As organic trace amount nutrients, it is desirable to add required substances such as vitamin B<sub>1</sub>, yeast extract and so forth in appropriate amounts. Other than these, potassium phosphate, magnesium sulfate, iron ions, manganese ions, and so forth are added in small amounts, as required.</p><p id="p0101" num="0101">The culture is preferably performed under aerobic conditions for 30 to 90 hours. The culture temperature is preferably controlled to be at 25°C to 37°C, and pH is preferably controlled to be 5 to 8 during the culture. For pH adjustment, inorganic or organic acidic or alkaline substances, ammonia gas, and so forth can be used.</p><p id="p0102" num="0102">L-cysteine, a related substance thereof, or a mixture thereof can be collected from the culture broth by a combination of ion-exchange resin method, precipitation<!-- EPO <DP n="44"> --> method, and other conventionally known methods.</p><p id="p0103" num="0103">L-cysteine obtained as described above can be used for production of L-cysteine derivatives. Examples of the L-cysteine derivatives include methylcysteine, ethylcysteine, carbocisteine, sulfocysteine, acetylcysteine, and so forth.</p><p id="p0104" num="0104">Furthermore, when a thiazolidine derivative of L-cysteine is accumulated in the medium, L-cysteine can be produced by collecting the thiazolidine derivative from the medium and breaking the reaction equilibrium between the thiazolidine derivative and L-cysteine so that L-cysteine is produced in a larger amount. Furthermore, when S-sulfocysteine is accumulated in the medium, it can be converted into L-cysteine by reduction using a reducing agent such as dithiothreitol.</p><p id="p0105" num="0105">Moreover, L-cysteine, a related substance thereof, or a mixture thereof can also be produced by adding pantothenic acid to the medium instead of modifying an L-cysteine-producing bacterium so that the L-aspartate-α-decarboxylase activity is increased. Namely, another embodiment of the method of the present invention (henceforth referred to as the second method of the present invention) is a method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises culturing a bacterium having L-cysteine-producing ability in a medium containing pantothenic acid, and collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</p><p id="p0106" num="0106">The bacterium having L-cysteine-producing ability<!-- EPO <DP n="45"> --> used for the second method of the present invention may be modified or may not be modified so that the L-aspartate-α-decarboxylase activity is increased. That is, modifying an L-cysteine-producing bacterium so that the L-aspartate-α-decarboxylase activity is increased, and adding pantothenic acid to the medium can be combined.</p><p id="p0107" num="0107">The contained amount of pantothenic acid in the medium is preferably 1 mg/L or higher, more preferably 2 mg/L or higher, still more preferably 5 mg/L or higher, particularly preferably 10 mg/L or higher. Although the maximum contained amount of pantothenic acid is not particularly limited, it can be, for example, 10 g/L or lower, or 1 g/L or lower. Pantothenic acid can be a free acid or pantothenate salt, or can be an arbitrary mixture of them. Type of pantothenate salt is not particularly limited, and examples include calcium salt, sodium salt, and so forth.</p><p id="p0108" num="0108">Pantothenic acid can be contained in the medium over the entire period of the culture, or contained in the medium over only a part of the culture period. For example, if the method of the present invention comprises the stage of proliferating the L-cysteine-producing bacterium, and the stage of producing and accumulating L-cysteine, it is sufficient that pantothenic acid is contained in the medium during at least the stage of producing and accumulating L-cysteine, and pantothenic acid may be or may not be contained in the medium during the stage of proliferating the L-cysteine-producing bacterium. Further, pantothenic acid can be contained in the medium over the entire period or a part of the period of the stage of producing and accumulating L-cysteine. For example, the contained amount<!-- EPO <DP n="46"> --> of pantothenic acid does not need to be within the aforementioned range over the entire period of the stage of producing and accumulating L-cysteine, that is, pantothenic acid can be contained in the medium at a contained amount within the aforementioned range in an early period of that stage, and the contained amount of pantothenic acid can be decreased with lapse of culture time. Further, pantothenic acid can be supplementarily added continuously or intermittently.</p><p id="p0109" num="0109">In the second method of the present invention, so long as a medium containing pantothenic acid is used, the same medium components and the same culture conditions as those of the method of using the bacterium of the present invention mentioned above can be used.</p><heading id="h0015">Example</heading><p id="p0110" num="0110">Hereafter, the present invention will be more specifically explained with reference to an example. In the following example, cysteine means L-cysteine.</p><heading id="h0016">&lt;Example&gt;</heading><heading id="h0017">(1) Construction of plasmids carrying <i>panD</i> genes derived from <i>C. glutamicum</i> 2256 strain, <i>E. coli</i> MG1655 strain, <i>P. ananatis</i> SC17 strain, and <i>B. subtilis</i> 168 strain</heading><p id="p0111" num="0111">In order to enhance the L-aspartate-α-decarboxylase activity, plasmids for <i>panD</i> gene expression carrying various <i>panD</i> genes were constructed by the following procedures.</p><p id="p0112" num="0112">By PCR using the genomic DNA of the <i>C. glutamicum</i> 2256 strain (ATCC 13869) as the template as well as primers<!-- EPO <DP n="47"> --> panD(Cg)-FW (CCAAGCTTATGGCATTCCAATAGTCAGG, SEQ ID NO: 1) and panD(Cg)-RV (CGAAGCTTGGGAAAAAGACGGCTCTACC, SEQ ID NO: 2), a <i>panD</i>(Cg) gene fragment of about 900 bp containing a region from about 300 bp upstream of the <i>panD</i> gene to about 200 bp downstream of the <i>panD</i> gene was amplified. The aforementioned primers were designed so as to have a site for the restriction enzyme <i>Hind</i>III at the 5' ends. PCR was performed by using Pyrobest polymerase (Takara) in the standard reaction composition described in the protocol of the polymerase, and the reaction condition was as follows: 94°C for 5 minutes, following 30 cycles of 98°C for 5 seconds, 55°C for 5 seconds, and 72°C for 1 minute. The obtained fragment was treated with <i>Hind</i>III, and subcloned by inserting it into pSTV29 (Takara) at the <i>Hind</i>III site, and it was confirmed that the amplified sequence was correct. A fragment excised again from the plasmid with <i>Hind</i>III was inserted into pMW218 (Takara) digested with the same enzyme in the same direction as that of the <i>lacZ</i> gene on the vector thereby to obtain a plasmid pMW218-panD(Cg) (kanamycin resistance marker), in which the <i>panD</i> gene of the <i>C. glutamicum</i> 2256 strain was cloned.</p><p id="p0113" num="0113">Similarly, by PCR using the genomic DNA of the E. coli MG1655 strain (ATCC 47076) as the template as well as primers panD(Ec)-FW (ATGATTCGCACGATGCTGCAGG, SEQ ID NO: 3) and panD(Ec)-RV (TCAAGCAACCTGTACCGGAATCG, SEQ ID NO: 4), a <i>panD</i>(Ec) gene fragment was obtained. PCR was performed on the same conditions as mentioned above. The obtained fragment was inserted into pMW218 digested with <i>SmaI</i> in the same direction as that of the <i>lacZ</i> gene on the vector to obtain a plasmid pMW218-panD(Ec) (kanamycin resistance marker), in which the <i>panD</i> gene of the <i>E. coli</i> MG1655 strain was cloned. The cloned <i>panD</i> gene is expressed by<!-- EPO <DP n="48"> --> read through from the <i>lac</i> promoter on the vector.</p><p id="p0114" num="0114">Similarly, by PCR using the genomic DNA of the P. <i>ananatis</i> SC17 strain (FERM BP-11091) as the template, as well as primers panD(Pa)-FW (GTAAAGGCTGCAGGTCGTATTTTTGGCTGT, SEQ ID NO: 5) and panD(Pa)-RW (GTTCTATATCGCGGTCTACTTCCTGATTCA, SEQ ID NO: 6), a <i>panD</i>(Pa) gene fragment was obtained. PCR was performed by using Pyrobest polymerase (Takara) in the standard reaction composition described in the protocol of the polymerase, and the reaction condition was as follows: 94°C for 1 minutes, following 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute was repeated 30 times. The obtained fragment was inserted into pSTV29 digested with <i>SmaI</i> in the same direction as that of the <i>lacZ</i> gene on the vector to obtain a plasmid pSTV29-panD(Pa) (chroramphenicol resistance marker), in which the <i>panD</i> gene of the P. <i>ananatis</i> SC 17 strain was cloned. The cloned <i>panD</i> gene is expressed by read through from the <i>lac</i> promoter on the vector.</p><p id="p0115" num="0115">A plasmid pCR-panD(Bs) is a plasmid carrying a region containing the <i>panD</i> gene of the <i>B. subtilis</i> 168 strain (ATCC 23857). pCR-panD(Bs) had a structure that the region of 2350947 to 2353681 bp of the genome of the <i>B. subtilis</i> 168 strain (according to the genome database SubtiList, http://genolist.pasteur.fr/SubtiList/) was inserted into the pMW218 vector (Nippon Gene) at the <i>Bam</i>HI site by using the <i>Sau</i>3AI sites at the both ends. The <i>panD</i> gene and franking regions thereof of the <i>B. subtilis</i> 168 strain can be readily obtained by such a conventional technique as PCR, and a plasmid having a structure similar to that of pCR-panD(Bs) suitable for the object of this experiment can be<!-- EPO <DP n="49"> --> constructed.</p><heading id="h0018">(2) Construction of <i>P. ananatis</i> cysteine-producing strain SC17intE511-2</heading><p id="p0116" num="0116">In order to investigate the effect of enhancing expression of various <i>panD</i> genes on the cysteine production, <i>P. ananatis</i> SC17intE511-2 strain having cysteine-producing ability was constructed by inserting a gene coding for an inhibition-desensitized type SAT into the chromosome of the <i>P. ananatis</i> SC17 strain according to the following procedures.</p><p id="p0117" num="0117">The plasmid pMIV-CysE5 (Japanese Patent Laid-open No. <patcit id="pcit0064" dnum="JP2009232844A"><text>2009-232844</text></patcit>) carries the CysE5 cassette containing the gene (<i>cysES</i>) encoding a mutant SAT desensitized to feedback inhibition by L-cysteine (<patcit id="pcit0065" dnum="US20050112731A1"><text>U.S. Patent Published Application No. 20050112731(A1</text></patcit>)) and a chloramphenicol resistance gene. The tetracycline resistance gene excised from the plasmid pACYC184 at <i>Eco</i>88I<i>-Xba</i>I was blunt-ended, and inserted into similarly blunt-ended PvuI site of the pMIV-CysE5 thereby to construct pMT-CysE5. The CysE5 cassette was introduced into the chromosome of the <i>P. ananatis</i> wild strain, SC17 strain, by using the obtained pMT-CysE5 and a conventional mini-Mu phage system utilizing pMH10 as a helper (<patcit id="pcit0066" dnum="EP1149911A"><text>EP 1149911 (A</text></patcit>)). Selection of the transformants was performed by using chloramphenicol resistance as the marker. About 50 of transformants in which the CysE5 cassette introduced into the chromosome were picked up, and cultured for cysteine production. As a result, most of the clones produced 0.2 to 0.3 g/L of cysteine. Among them, one clone produced about 0.7 g/L of cysteine, and this clone was designated as SC17intE511. The genomic DNA of SC17intE511 was extracted, and the obtained genomic DNA was introduced<!-- EPO <DP n="50"> --> into SC17 by electroporation to again construct a strain in which the CysE5 cassette was introduced into the chromosome. Selection of the transformants was performed on the basis of chloramphenicol resistance as a marker. About 20 of transformants were picked up, and cultured for cysteine production. As a result, almost all of the clones produced 0.2 to 0.3 g/L of cysteine. The SAT activity of some clones among these strains was measured by a conventional method (<patcit id="pcit0067" dnum="US20050112731A"><text>U.S. Patent Published Application No. 20050112731(A</text></patcit>), and a clone showing the SAT activity comparable to that of SC17intE511 as the parent strain was selected, and designated as SC17intE511-2.</p><heading id="h0019">(3) Effects of enhancing expression of various <i>panD</i> genes and addition of pantothenic acid on cysteine production in <i>P. ananatis</i> cysteine-producing strain</heading><p id="p0118" num="0118">In order to investigate the effect of enhancing expression of various <i>panD</i> genes on cysteine production, the <i>P. ananatis</i> cysteine-producing strain SC17intE511-2 was transformed with the plasmids pMW218-panD(Cg), pSTV28-panD(Pa), and pCR-panD(Bs) each, which were constructed as described above. <i>P. ananatis</i> was transformed by electroporation in a conventional manner, and selection of the transformants was performed on the LB agar medium (5 g/L of yeast extract, 10 g/L of tryptone, 10 g/L of sodium chloride, 15 g/L of agar) containing the antibiotic corresponding to the antibiotic resistance marker of each plasmid (25 mg/L of chloramphenicol or 20 mg/L of kanamycin). Moreover, as control strains, the strains transformed with empty vectors were also obtained.</p><p id="p0119" num="0119">Cysteine production culture was performed by using the SC17intE511-2/pMW218-panD(Cg) strain, SC17intE511-2/pMW218<!-- EPO <DP n="51"> --> strain, the SC17intE511-2/pSTV28-panD(Pa) strain, the SC17intE511-2/pSTV29 strain, the SC17intE511-2/pCR-panD(Bs) strain, and the SC17intE511-2/pCR strain obtained as described above, and the amounts of produced cysteine were compared. Cysteine production culture was also performed by using the SC17intE511-2/pSTV29 strain in a medium containing 20 mg/L of calcium pantothenate to investigate the effect of addition of pantothenic acid on cysteine production. For the culture, a cysteine production medium of the following composition containing the antibiotic corresponding to the antibiotic resistance marker of each plasmid (25 mg/L of chloramphenicol or 20 mg/L of kanamycin) was used.</p><heading id="h0020">&lt;Composition of cysteine production medium&gt;</heading><p id="p0120" num="0120"><tables id="tabl0001" num="0001"><table frame="none"><tgroup cols="2" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="58mm"/><colspec colnum="2" colname="col2" colwidth="20mm"/><tbody><row><entry>Ammonium sulfate</entry><entry>15 g/L</entry></row><row><entry>Potassium dihydrogenphosphate</entry><entry>1.5 g/L</entry></row><row><entry>Magnesium sulfate heptahydrate</entry><entry>1 g/L</entry></row><row><entry>Thiamine hydrochloride</entry><entry>0.1 mg/L</entry></row><row><entry>Ferrous sulfate heptahydrate</entry><entry>1.7 mg/L</entry></row><row><entry>Sodium molybdate dihydrate</entry><entry>0.15 mg/L</entry></row><row><entry>Cobalt chloride hexahydrate</entry><entry>0.7 mg/L</entry></row><row><entry>Manganese chloride tetrahydrate</entry><entry>1.6 mg/L</entry></row><row><entry>Zinc sulfate heptahydrate</entry><entry>0.3 mg/L</entry></row><row><entry>Copper sulfate pentahydrate</entry><entry>0.25 mg/L</entry></row><row><entry>Tryptone</entry><entry>0.6 g/L</entry></row><row><entry>Yeast extract</entry><entry>0.3 g/L</entry></row><row><entry>Sodium chloride</entry><entry>0.6 g/L</entry></row><row><entry>Calcium carbonate</entry><entry>20 g/L</entry></row><row><entry>L-Histidine hydrochloride monohydrate</entry><entry>135 mg/L</entry></row><row><entry>Sodium thiosulfate</entry><entry>4 g/L</entry></row><row><entry>Pyridoxine hydrochloride</entry><entry>2 mg/L</entry></row><row><entry>Glucose</entry><entry>60 g/L</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="52"> --></p><p id="p0121" num="0121">The cysteine production culture was performed according to the following procedures. Each cysteine-producing strain was spread on the LB agar medium containing chloramphenicol or kanamycin, and precultured overnight at 34°C. The cells corresponding to about 7 cm on the plate were scraped with an inoculating loop of 10 µl size (NUNC Blue Loop), and inoculated into 2 ml of the cysteine production medium contained in a large test tube (internal diameter, 23 mm; length, 20 cm). The amounts of inoculated cells were adjusted so that the cell amounts at the time of the start of the culture should be substantially the same. The culture was performed at 32°C with shaking. When glucose in the medium was completely consumed, the culture was terminated (about 13 to 16 hours), and the amount of cysteine produced in the medium was quantified. The culture was performed in quadruplicate for each strain. Cysteine was quantified by the method described by <nplcit id="ncit0036" npl-type="s"><text>Gaitonde, M.K. (Biochem. J., 1967 Aug., 104(2):627-33</text></nplcit>). Averages and standard deviations of the produced cysteine amounts are shown in Table 1. As shown in Table 1, it was revealed that both enhancing expression of various <i>panD</i> genes and addition of pantothenic acid increased cysteine production amount.</p><p id="p0122" num="0122">[Table 1]
<tables id="tabl0002" num="0002"><table frame="topbot"><title>Table 1</title><tgroup cols="3" colsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="54mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="middle">Effect of enhancing expression of various <i>panD</i> genes and addition of pantothenic acid on cysteine production in P.<i>ananatis</i></entry></row><row><entry align="center" valign="middle">Vector</entry><entry align="center" valign="middle">Cysteine (mg/L)</entry><entry align="center" valign="middle">SD (mg/L)</entry></row></thead><tbody><row><entry align="center" valign="middle">pMW218</entry><entry align="center" valign="middle">56</entry><entry align="center" valign="middle">2.3</entry></row><!-- EPO <DP n="53"> --><row><entry align="center" valign="middle">pMW-panD(Cg)</entry><entry align="center" valign="middle">360</entry><entry align="center" valign="middle">44</entry></row><row><entry align="center" valign="middle">pCR</entry><entry align="center" valign="middle">105</entry><entry align="center" valign="middle">23</entry></row><row><entry align="center" valign="middle">pCR-panD(Bs)</entry><entry align="center" valign="middle">610</entry><entry align="center" valign="middle">190</entry></row><row><entry align="center" valign="middle">pSTV29</entry><entry align="center" valign="middle">134</entry><entry align="center" valign="middle">2.4</entry></row><row><entry align="center" valign="middle">pSTV-panD(Pa)</entry><entry align="center" valign="middle">561</entry><entry align="center" valign="middle">41</entry></row><row><entry align="center" valign="middle">pSTV29 + 20 mg/L pantothenate</entry><entry align="center" valign="middle">421</entry><entry align="center" valign="middle">24</entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="54mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify">SD: Standard Deviation</entry></row></tbody></tgroup></table></tables></p><heading id="h0021">(4) Construction of plasmid carrying inhibition-desensitized-type SAT gene, pACYC-E1</heading><p id="p0123" num="0123">A plasmid pACYC-E1 carrying a gene coding for an inhibition-desensitized type SAT, for use in construction of a cysteine-producing bacterium, was constructed by the following procedures.</p><p id="p0124" num="0124">The plasmid pACYC-DE1 carries the <i>cysEX</i> gene coding for a mutant SAT desensitized to feedback inhibition by L-cysteine (<patcit id="pcit0068" dnum="US5972663A"><text>U.S. Patent No. 5,972,663</text></patcit>), and the <i>ydeD</i> gene coding for a secretion factor for cysteine and acetylserine. A cysteine-producing bacterium that can produce a marked amount of cysteine can be prepared by introducing this plasmid. pACYC-DE1 can be constructed by substantially the same method as the construction method of pACYC-DES described in <patcit id="pcit0069" dnum="EP1528108B1"><text>EP 1528108 B1</text></patcit>. The difference between pACYC-DE1 and pACYC-DES is that pACYC-DE1 does not carry the <i>serA5</i> gene, and that is, pACYC-DE1 corresponds to the pACYC184 vector carrying only two of the genes, the <i>cysEX</i> gene and the <i>ydeD</i> gene. In pACYC-DE1, both the <i>cysEX</i> gene and <i>ydeD</i> gene are ligated to the <i>ompA</i> promoter. This pACYC-DE1 was digested with <i>Mnu</i>I, and self-ligated to delete a region of about 330 bp inside the <i>ydeD</i> gene. The plasmid constructed as described above, which carried the<!-- EPO <DP n="54"> --> <i>cysEX</i> gene, but lost the function of the <i>ydeD</i> gene, was used in the following experiments as pACYC-E1.</p><heading id="h0022">(5) Effects of enhancing expression of various <i>panD</i> genes and addition of pantothenic acid on cysteine production in <i>E. coli</i> cysteine-producing strain</heading><p id="p0125" num="0125">Whether the effects of enhancing expression of the <i>panD</i> gene and addition of pantothenic acid could also be obtained in bacteria other than <i>P</i>. <i>ananatis</i> was investigated by using an <i>E</i>. <i>coli</i> cysteine-producing strain.</p><p id="p0126" num="0126">As the E. <i>coli</i> cysteine-producing strain, a transformant MG1655/pACYC-E1 obtained by introducing pACYC-El (tetracycline resistance marker) mentioned above into the E. <i>coli</i> MG1655 strain by electroporation was used.</p><p id="p0127" num="0127">This <i>E</i>. <i>coli</i> cysteine-producing bacterium MG1655/pACYC-E1 was transformed with pMW218-panD(Cg) or pMW218-panD(Ec). The <i>E</i>. <i>coli</i> strain was transformed by electroporation in a conventional manner, and selection of the transformants was performed on the LB agar medium containing the antibiotic corresponding to the antibiotic resistance marker of each plasmid (25 mg/L of chloramphenicol or 20 mg/L of kanamycin). Moreover, as a control strain, the strain transformed with empty vector pMW218 was also obtained.</p><p id="p0128" num="0128">Cysteine production culture was performed by using the MG1655/pACYC-E1/pMW-panD(Cg) strain, the MG1655/pACYC-E1/pMW-panD(Ec) strain, and the MG1655/pACYC-E1/pMW-218 strain obtained as described above, and the amounts of produced cysteine were compared. Cysteine production culture was also performed by using the MG1655/pACYC-E1/pMW-218<!-- EPO <DP n="55"> --> strain in the medium containing 10 mg/L of calcium pantothenate to investigate effect of addition of pantothenic acid on cysteine production. The composition of the cysteine production medium used was the same as that mentioned above, except that the glucose concentration was 40 g/L. In the same manner as described above, the culture was continued for 19 to 22 hours until glucose in the medium was completely consumed, and the amount of cysteine produced in the medium was quantified. The culture was performed in quadruplicate for each strain. Averages and standard deviations of the produced cysteine amounts are shown in Table 2. As shown in Table 2, it was revealed that both enhancing expression of various <i>panD</i> genes and addition of pantothenic acid increased cysteine production amount also in <i>E</i>. <i>coli.</i></p><p id="p0129" num="0129">[Table 2]
<tables id="tabl0003" num="0003"><table frame="bottom"><title>Table 2</title><tgroup cols="3" colsep="0"><colspec colnum="1" colname="col1" colwidth="60mm"/><colspec colnum="2" colname="col2" colwidth="54mm"/><colspec colnum="3" colname="col3" colwidth="52mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="middle">Effect of enhancing expression of various <i>panD</i> genes and addition of pantothenic acid on cysteine production in <i>E</i>. <i>coli</i></entry></row><row><entry align="center" valign="middle">Vector</entry><entry align="center" valign="middle">Cysteine (mg/L)</entry><entry align="center" valign="middle">SD (mg/L)</entry></row></thead><tbody><row><entry align="center" valign="middle">pMW218</entry><entry align="center" valign="middle">366</entry><entry align="center" valign="middle">29</entry></row><row><entry align="center" valign="middle">pMW-panD(Cg)</entry><entry align="center" valign="middle">742</entry><entry align="center" valign="middle">47</entry></row><row><entry align="center" valign="middle">pMW-panD(Ec)</entry><entry align="center" valign="middle">622</entry><entry align="center" valign="middle">18</entry></row><row><entry align="center" valign="middle">pMW218</entry><entry align="center" valign="middle">412</entry><entry align="center" valign="middle">78</entry></row><row><entry align="center" valign="middle">pMW218 + 10 mg/L pantothenate</entry><entry align="center" valign="middle">518</entry><entry align="center" valign="middle">66</entry></row></tbody></tgroup><tgroup cols="3" rowsep="0"><colspec colnum="1" colname="col1" colwidth="60mm"/><colspec colnum="2" colname="col2" colwidth="54mm"/><colspec colnum="3" colname="col3" colwidth="52mm"/><tbody><row><entry namest="col1" nameend="col3" align="justify">SD: Standard Deviation</entry></row></tbody></tgroup></table></tables></p><heading id="h0023">(6) Investigation of added concentration of pantothenic acid</heading><p id="p0130" num="0130">Since it was revealed above that cysteine production<!-- EPO <DP n="56"> --> was increased by addition of pantothenic acid, the pantothenic acid concentration required for obtaining the effect was investigated. '</p><p id="p0131" num="0131">The <i>P</i>. <i>ananatis</i> SC17intE511-2/pSTV29 strain was cultured in the cysteine production medium containing calcium pantothenate at a concentration range of 10 mg/L to 100 µg/L, and cysteine production amount was measured. The composition of the cysteine production medium used was the same as that mentioned above, except that the glucose concentration was 60 g/L. The culture was performed for about 16 to 20 hours in quadruplicate for each concentration. Averages and standard deviations of the produced cysteine amounts are shown in <figref idrefs="f0002 f0003 f0004">Fig. 2</figref>. It was revealed that the cysteine production amount increased in a pantothenic acid concentration-dependent manner when 1 mg/L or more of calcium pantothenate was added.</p><heading id="h0024">(7) Cysteine production with various <i>panD</i> gene expression-enhanced strains</heading><p id="p0132" num="0132">Various <i>panD</i> fragments are amplified by PCR using the front 20 bp sequence and the end 20 bp sequence of nucleotide sequences of genes coding for various PanD proteins, such as the nucleotide sequences of SEQ ID NOS: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, and 59, as the forward (Fw) primer and the reverse (Rv) primer, respectively, which consists of 94°C for 5 minutes, following 30 cycles of 98°C for 5 seconds, 55°C for 5 seconds, and 72°C for 1 minute is repeated 30 times. The obtained fragment is placed under control by an appropriate promoter. For example, by introducing the obtained fragment into pSTV28 (TaKaRa) at the <i>Sma</i>I site so as to be<!-- EPO <DP n="57"> --> under the control of the <i>lac</i> promoter, an expression vector of the <i>panD</i> gene is constructed. By introducing the obtained <i>panD</i> gene expression vector into a cysteine-producing bacterium, for example, <i>P. ananatis</i> SC17intE511-2, by electroporation, and performing cysteine production culture by the method described above, cysteine can be efficiently produced.</p><heading id="h0025">Industrial Applicability</heading><p id="p0133" num="0133">According to the present invention, L-cysteine-producing ability of bacteria can be improved, and L-cysteine, a related substance thereof, or a mixture thereof can be efficiently produced.</p><heading id="h0026">Explanation of Sequence Listing</heading><p id="p0134" num="0134"><ul><li>SEQ ID NO: 1: Primer for amplification of <i>C</i>. <i>glutamicum</i> 2256 <i>panD</i> gene</li><li>SEQ ID NO: 2: Primer for amplification of <i>C</i>. <i>glutamicum</i> 2256 <i>panD</i> gene</li><li>SEQ ID NO: 3: Primer for amplification of <i>E</i>. <i>coli</i> MG1655 <i>panD</i> gene</li><li>SEQ ID NO: 4: Primer for amplification of <i>E</i>. <i>coli</i> MG1655 <i>panD</i> gene</li><li>SEQ ID NO: 5: Primer for amplification of <i>P</i>. <i>ananatis</i> SC17 <i>panD</i> gene</li><li>SEQ ID NO: 6: Primer for amplification of <i>P</i>. <i>ananatis</i> SC17 <i>panD</i> gene</li><li>SEQ ID NO: 7: Nucleotide sequence of <i>E</i>. <i>coli</i> MG1655 <i>panD</i> gene</li><li>SEQ ID NO: 8: Amino acid sequence of <i>E</i>. <i>coli</i> MG1655 PanD protein</li><li>SEQ ID NO: 9: Nucleotide sequence of <i>P</i>. <i>ananatis</i> SC17 <i>panD</i><!-- EPO <DP n="58"> --> gene</li><li>SEQ ID NO: 10: Amino acid sequence of <i>P</i>. <i>ananatis</i> SC17 PanD protein</li><li>SEQ ID NO: 11: Nucleotide sequence of <i>C</i>. <i>glutamicum</i> 2256 <i>panD</i> gene</li><li>SEQ ID NO: 12: Amino acid sequence of <i>C</i>. <i>glutamicum</i> 2256 PanD protein</li><li>SEQ ID NO: 13: Nucleotide sequence of <i>B. subtilis</i> 168 <i>panD</i> gene</li><li>SEQ ID NO: 14: Amino acid sequence of <i>B. subtilis</i> 168 PanD protein</li><li>SEQ ID NO: 15: Nucleotide sequence of <i>Arthrobacter aurescens panD</i> gene</li><li>SEQ ID NO: 16: Amino acid sequence of <i>Arthrobacter aurescens</i> PanD protein</li><li>SEQ ID NO: 17: Nucleotide sequence of <i>Bacteroides fragilis panD</i> gene</li><li>SEQ ID NO: 18: Amino acid sequence of <i>Bacteroides fragilis</i> PanD protein</li><li>SEQ ID NO: 19: Nucleotide sequence of <i>Bacteroides vulgatus panD</i> gene</li><li>SEQ ID NO: 20: Amino acid sequence of <i>Bacteroides vulgatus</i> PanD protein</li><li>SEQ ID NO: 21: Nucleotide sequence of <i>Brevibacterium lactofermentum panD</i> gene</li><li>SEQ ID NO: 22: Amino acid sequence of <i>Brevibacterium lactofermentum</i> PanD protein</li><li>SEQ ID NO: 23: Nucleotide sequence of <i>Chlorobium tepidum panD</i> gene</li><li>SEQ ID NO: 24: Amino acid sequence of <i>Chlorobium tepidum</i> PanD protein</li><li>SEQ ID NO: 25: Nucleotide sequence of <i>Citrobacter koseri panD</i> gene<!-- EPO <DP n="59"> --></li><li>SEQ ID NO: 26: Amino acid sequence of <i>Citrobacter koseri</i> PanD protein</li><li>SEQ ID NO: 27: Nucleotide sequence of <i>Clavibacter michiganensis panD</i> gene</li><li>SEQ ID NO: 28: Amino acid sequence of <i>Clavibacter michiganensis</i> PanD protein</li><li>SEQ ID NO: 29: Nucleotide sequence of <i>Corynebacterium jeikeium panD</i> gene</li><li>SEQ ID NO: 30: Amino acid sequence of <i>Corynebacterium jeikeium</i> PanD protein</li><li>SEQ ID NO: 31: Nucleotide sequence of <i>Cytophaga hutchinsonii panD</i> gene</li><li>SEQ ID NO: 32: Amino acid sequence of <i>Cytophaga hutchinsonii</i> PanD protein</li><li>SEQ ID NO: 33: Nucleotide sequence of <i>Enterobacter sakazakii panD</i> gene</li><li>SEQ ID NO: 34: Amino acid sequence of <i>Enterobacter sakazakii</i> PanD protein</li><li>SEQ ID NO: 35: Nucleotide sequence of <i>Flavobacterium johnsoniae panD</i> gene</li><li>SEQ ID NO: 36: Amino acid sequence of <i>Flavobacterium johnsoniae</i> PanD protein</li><li>SEQ ID NO: 37: Nucleotide sequence of <i>Flavobacterium psychrophilum panD</i> gene</li><li>SEQ ID NO: 38: Amino acid sequence of <i>Flavobacterium psychrophilum</i> PanD protein</li><li>SEQ ID NO: 39: Nucleotide sequence of <i>Klebsiella pneumoniae panD</i> gene</li><li>SEQ ID NO: 40: Amino acid sequence of <i>Klebsiella pneumoniae</i> PanD protein</li><li>SEQ ID NO: 41: Nucleotide sequence of <i>Methylophilus methylotrophus panD</i> gene</li><li>SEQ ID NO: 42: Amino acid sequence of <i>Methylophilus<!-- EPO <DP n="60"> --> methylotrophus</i> PanD protein</li><li>SEQ ID NO: 43: Nucleotide sequence of <i>Mycobacterium avium panD</i> gene</li><li>SEQ ID NO: 44: Amino acid sequence of <i>Mycobacterium avium</i> PanD protein</li><li>SEQ ID NO: 45: Nucleotide sequence of <i>Parabacteroides distasonis panD</i> gene</li><li>SEQ ID NO: 46: Amino acid sequence of <i>Parabacteroides distasonis</i> PanD protein</li><li>SEQ ID NO: 47: Nucleotide sequence of <i>Porphyromonas gingivalis panD</i> gene</li><li>SEQ ID NO: 48: Amino acid sequence of <i>Porphyromonas gingivalis</i> PanD protein</li><li>SEQ ID NO: 49: Nucleotide sequence of <i>Rhodococcus</i> sp. <i>panD</i> gene</li><li>SEQ ID NO: 50: Amino acid sequence of <i>Rhodococcus</i> sp. PanD protein</li><li>SEQ ID NO: 51: Nucleotide sequence of <i>Saccharopolyspora erythraea panD</i> gene</li><li>SEQ ID NO: 52: Amino acid sequence of <i>Saccharopolyspora erythraea</i> PanD protein</li><li>SEQ ID NO: 53: Nucleotide sequence of <i>Salinibacter ruber panD</i> gene</li><li>SEQ ID NO: 54: Amino acid sequence of <i>Salinibacter ruber</i> PanD protein</li><li>SEQ ID NO: 55: Nucleotide sequence of <i>Salmonella enterica panD</i> gene</li><li>SEQ ID NO: 56: Amino acid sequence of <i>Salmonella enterica</i> PanD protein</li><li>SEQ ID NO: 57: Nucleotide sequence of <i>Streptomyces coelicolor panD</i> gene</li><li>SEQ ID NO: 58: Amino acid sequence of <i>Streptomyces coelicolor</i> PanD protein<!-- EPO <DP n="61"> --></li><li>SEQ ID NO: 59: Nucleotide sequence of <i>Thermobifida fusca panD</i> gene</li><li>SEQ ID NO: 60: Amino acid sequence of <i>Thermobifida fusca</i> PanD protein</li></ul><!-- EPO <DP n="62"> --><img id="ib0001" file="imgb0001.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="63"> --><img id="ib0002" file="imgb0002.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="64"> --><img id="ib0003" file="imgb0003.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="65"> --><img id="ib0004" file="imgb0004.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="66"> --><img id="ib0005" file="imgb0005.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="67"> --><img id="ib0006" file="imgb0006.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="68"> --><img id="ib0007" file="imgb0007.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="69"> --><img id="ib0008" file="imgb0008.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="70"> --><img id="ib0009" file="imgb0009.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="71"> --><img id="ib0010" file="imgb0010.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="72"> --><img id="ib0011" file="imgb0011.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="73"> --><img id="ib0012" file="imgb0012.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="74"> --><img id="ib0013" file="imgb0013.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="75"> --><img id="ib0014" file="imgb0014.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="76"> --><img id="ib0015" file="imgb0015.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="77"> --><img id="ib0016" file="imgb0016.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="78"> --><img id="ib0017" file="imgb0017.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="79"> --><img id="ib0018" file="imgb0018.tif" wi="152" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="80"> --><img id="ib0019" file="imgb0019.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="81"> --><img id="ib0020" file="imgb0020.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="82"> --><img id="ib0021" file="imgb0021.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="83"> --><img id="ib0022" file="imgb0022.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="84"> --><img id="ib0023" file="imgb0023.tif" wi="150" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="85"> --><img id="ib0024" file="imgb0024.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="86"> --><img id="ib0025" file="imgb0025.tif" wi="148" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="87"> --><img id="ib0026" file="imgb0026.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="88"> --><img id="ib0027" file="imgb0027.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="89"> --><img id="ib0028" file="imgb0028.tif" wi="147" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="90"> --><img id="ib0029" file="imgb0029.tif" wi="136" he="66" img-content="dna" img-format="tif"/></p></description><claims mxw-id="PCLM56977423" lang="EN" load-source="patent-office"><!-- EPO <DP n="91"> --><claim id="c-en-0001" num="0001"><claim-text>A bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability, and is modified so that L-aspartate-α-decarboxylase activity is increased.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The bacterium according to claim 1, wherein the L-aspartate-α-decarboxylase activity is increased by increasing the expression amount of <i>panD</i> gene.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The bacterium according to claim 2, wherein the expression amount of the <i>panD</i> gene is increased by increasing the copy number of the <i>panD</i> gene or by modifying an expression control sequence of the <i>panD</i> gene.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The bacterium according to claim 2 or 3, wherein the <i>panD</i> gene is a DNA coding for a protein of the following (A) or (B):
<claim-text>(A) a protein comprising the amino acid sequence of SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60;</claim-text>
<claim-text>(B) a protein comprising the amino acid sequence of SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60 but which includes one or several amino acid substitutions, deletions, insertions, or additions, and having the L-aspartate-α-decarboxylase activity.</claim-text></claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The bacterium according to any one of claims 2 to 4, wherein the <i>panD</i> gene is a DNA of the following (a) or (b):
<claim-text>(a) a DNA comprising the nucleotide sequence of SEQ ID NO:<!-- EPO <DP n="92"> --> 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, or 59;</claim-text>
<claim-text>(b) a DNA hybridizable with a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, or 59, or a probe that can be prepared from the nucleotide sequence under stringent conditions, and coding for a protein having the L-aspartate-α-decarboxylase activity.</claim-text></claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The bacterium according to claim 4 or 5, wherein the protein having the L-aspartate-α-decarboxylase activity has the following characteristics (1) and (2):
<claim-text>(1) the glycine residue of position 24 and the serine residue of position 25 are conserved;</claim-text>
<claim-text>(2) the lysine residue of position 9, the histidine residue of position 11, the threonine residue of position 57, and the tyrosine residue of position 58 are conserved.</claim-text></claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The bacterium according to claim 6, wherein the protein having the L-aspartate-α-decarboxylase activity further has the following characteristic (3): (3) the valine residue of position 15, the threonine residue of position 16, the leucine residue of position 20, the tyrosine residue of position 22, the aspartic acid residue of position 29, the glutamic acid residue of position 42, the asparagine residue of position 51, the glycine residue of position 52, the arginine residue of position 54, the isoleucine residue of position 60, the asparagine residue of position 72, the glycine residue of position 73, the alanine residue of position 74, the alanine residue of position 75, the alanine residue of position 76, the aspartic acid residue of position 83, and<!-- EPO <DP n="93"> --> the isoleucine residue of position 86 are conserved.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The bacterium according to any one of claims 1 to 7, which further has one or more of the following characteristics (1) to (3):
<claim-text>(1) it is modified so that the serine acetyltransferase activity is increased;</claim-text>
<claim-text>(2) L-cysteine excretion system is enhanced;</claim-text>
<claim-text>(3) it is modified so that the 3-phosphoglycerate dehydrogenase activity is increased.</claim-text></claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The bacterium according to any one of claims 1 to 8, which is an <i>Escherichia</i> bacterium.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The bacterium according to claim 9, which is <i>Escherichia coli.</i></claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The bacterium according to any one of claims 1 to 8, which is a <i>Pantoea</i> bacterium.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>The bacterium according to claim 11, which is <i>Pantoea ananatis.</i></claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>A method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
<claim-text>culturing the bacterium according to any one of claims 1 to 12 in a medium; and</claim-text>
<claim-text>collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</claim-text></claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The method according to claim 13, wherein the medium contains pantothenic acid.<!-- EPO <DP n="94"> --></claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>A method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
<claim-text>culturing a bacterium belonging to the family <i>Enterobacteriaceae,</i> which has L-cysteine-producing ability, in a medium containing pantothenic acid; and</claim-text>
<claim-text>collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.</claim-text></claim-text></claim><claim id="c-en-0016" num="0016"><claim-text>The method according to claim 14 or 15, wherein the contained amount of pantothenic acid in the medium is 1 mg/L or more.</claim-text></claim><claim id="c-en-0017" num="0017"><claim-text>The method according to any one of claims 13 to 16, wherein the related substance of L-cysteine is L-cystine, a thiazolidine derivative, or L-methionine.</claim-text></claim></claims><drawings mxw-id="PDW16668124" load-source="patent-office"><!-- EPO <DP n="95"> --><figure id="f0001" num="1-1"><img id="if0001" file="imgf0001.tif" wi="156" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="96"> --><figure id="f0002" num="1-2"><img id="if0002" file="imgf0002.tif" wi="153" he="216" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="97"> --><figure id="f0003" num="1-2"><img id="if0003" file="imgf0003.tif" wi="130" he="217" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="98"> --><figure id="f0004" num="1-2"><img id="if0004" file="imgf0004.tif" wi="134" he="216" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="165" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="160" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="160" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
